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ABSTRACT

POTENTIAL ENHANCEMENT OF DIETARY ISOTHIOCYANATES COMBINATION
ON BIOLOGICAL ACTIVITIES
MAY 2017
KANYASIRI RAKARIYATHAM, B.S., CHIANG MAI UNIVERSITY, THAILAND
M.S., CALIFORNIA STATE UNIVERSITY FULLERTON
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Hang Xiao

Isothiocyanates (ITCs) such as allyl isothiocyanate (AIT) and sulforaphane (SFN) are wellknown bioactives with wide range of beneficial properties, which may be consumed
simultaneously through diets containing cruciferous vegetables. However, biological activities of
ITCs in combinations had not been well defined. The present study evaluated the potential
efficacy of AIT, SFN and their combinations on three important biological properties: anticancer,
anti-inflammation and antioxidant.
Our results showed that the combination between AIT and SFN led to a stronger growth
inhibition on A549 non-small cell lung cancer cells than treatments with the individual
compounds. The enhanced effect was proved to be synergistic by isobologram analysis. Flow
cytometry analysis demonstrated that the combination treatment caused more extensive cell
cycle arrest and cellular apoptosis in the cancer cells than the singular treatment. In addition, a
synergy between AIT and SFN was also observed in their anti-cell migration. It is noteworthy
that the AIT-SFN combination resulted in the production of intracellular reactive oxygen species
(ROS), which might contribute to their inhibitory effects on cancer cells.
In terms of anti-inflammation, the combination of AIT and SFN both pairing between
themselves (AIT-SFN), and pairing with other dietary bioactives (AIT-CUR, AIT-LUT, and SFN-LUT)

vi

enhanced this beneficial property in comparison to a single compound utilization in
lipopolysaccharide-induced RAW 264.7 macrophages. We observed dose-dependent and
synergistic inhibition of pro-inflammatory molecules production such as nitric oxide, and
interleukin-6. Western blotting showed corresponding information that the combined
treatment reduced the expression levels of pro-inflammatory proteins and increased the
expression of an antioxidative protein, which could contribute to their anti-inflammatory
properties as well.
In addition, pretreatment of RAW 264.7 cells with the AIT-SFN combination provided
synergistic cytoprotective effects against tert-butyl hydroperoxide-induced oxidative damage by
increasing antioxidant effects, decreasing cellular ROS, and increasing viability of RAW 264.7
cells. These protective properties were completed through phase 2 antioxidant and
detoxification proteins, some of which had more dominant effects than the others, under a
partial regulation of Nrf2, and NF-B transcription factors.
Overall, this study proved a potential enhancement of dietary ITCs in combinations on
biological activities, and provided information for developing functional foods for health
benefits.
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CHAPTER 1
INTRODUCTION

Cancer is a major public health problem with high death rates in many parts of the
world. Although many techniques and therapies have been utilized to treat cancer, malignant
cells may reduce their dependence on one hallmark capability and become more dependent on
another, generating a status called drug resistance. This is because each of the hallmark
capabilities is regulated by redundant signaling pathways and cancerous cells can undergo
adaptation by mutation, epigenetic reprogramming, or remodeling of the stromal
microenvironment (1). Recently, there has been a growing body of evidence suggesting that the
combination of cancer chemopreventive agents may enhanced treatment efficacies through
distinct mechanisms (2). Among combinatorial treatments, utilizing dietary bioactive
components are of interest due to their none or few adverse effects and their multi-targeting
features, leading to reduction of side effects and minimizing the development of drug resistance
(3).
To date, little is known about the roles of dietary bioactives in combinations, which
represents a complex system including consumption of fruits and vegetables mix. The present
study was undertaken to evaluate the enhanced beneficial effects of dietary phytochemicals,
particularly allyl isothiocyanate (AIT) and sulforaphane (SFN), both of which are isothiocyanates
(ITCs), when they were combined together, and when each of them was combined with other
dietary bioactives such as luteolin (LUT), and curcumin (CUR). These bioactive compounds were
chosen based on their biological properties and their sources which are natural diet-based.
ITCs are naturally occurring molecules found in cruciferous vegetables from enzymatic
conversion of glucosinolates. They are suggested to be promising anticancer agents. Many of AIT
and SFN have displayed anticarcinogenic activities through various mechanisms including
1

reducing activation of carcinogens, reducing cancer cell proliferation, inducing cycle arrest
leading to apoptosis, and decreasing invasion and metastasis (4, 5). Besides, they also possess
anti-inflammatory and indirect antioxidant properties through regulations of well-known
transcription factors nuclear factor-B (NF-B), and nuclear transcription factor erythroid 2p45 related factor2 (Nrf2), respectively. Since ITCs have been proved to act through several
mechanistic targets, this attribute of the compounds may be effective and suitable for the
combinatorial therapeutic approach.
Polyphenols such as LUT and CUR can be found in a range of plant foods including
oregano, and turmeric, respectively. They possess direct antioxidant properties regarding their
chemical structures, that are capable to donate hydrogen or electron and stabilize a radical
species, as well as to bind transition metal ions such as iron and copper. They also have been
shown to exert strong indirect antioxidant by increasing activation of Nrf2. Their antiinflammatory activities can be achieved via suppressing the activation of NF-B and activator
protein-1 (AP-1) (6, 7). In addition, several mechanisms have been revealed in the cancer
chemopreventive activity of LUT and CUR including inhibition of angiogenesis, and induction of
apoptosis via reactive oxygen species (ROS) accumulation (8-10).
Regarding studies that reveal connections between oxidative stress, inflammation and
their deleterious effects on cancers (11), the present work studied chemopreventive effects,
anti-inflammatory properties, as well as the cytoprotective effect of AIT and SFN in combination.
In addition to the AIT-SFN combined treatment, other phytochemicals including LUT, and CUR
were also used to combine with the aforementioned bioactives and tested on their enhanced
anti-inflammatory properties. This project has a long-term goal to comprehend, and emphasize
the significance of using dietary phytochemicals in combinations for formulating and developing
functional food products that improve cancer prevention. The overall objective of this project is
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to enhance biological activities of anticancer, anti-inflammatory, and antioxidant properties
using dietary bioactive agents in combinations, including co-treatment of AIT and SFN. The
rationale of this research is from the distinct mechanisms of each bioactive compound that may
support each other’s effects when using in combination. Based on this rationale, our central
hypothesis is that a combination of dietary ITCs can enhance biological activities that are
anticancer, anti-inflammation, and oxidative damage prevention. To determine how any two
substances, act together, we consider the value of the combination index (CI) from isobologram
analysis, whether it is < 1, = 1, or > 1 so we know that the compounds are acting in synergistic,
additive, or antagonistic pattern, respectively. This hypothesis can be proved through the
following directions:

Specific Aim 1: To study combinatorial effects between AIT and SFN on
chemoprevention
AIT, SFN, and their combination in dimethyl sulfoxide (DMSO) vehicle will be used to
treat A549 non-small cell lung cancer cells, followed by cell viability determination. To find out
how the treatments work according to the reduction of cell proliferation, cell cycle arrest and
apoptosis were examined using flow cytometry. Cellular ROS was measured using
dichlorofluorescein diacetate (DCFH-DA). Cell migration was also observed through a scratch
assay as an indicator of anti-metastatic property. To confirm and support the result, molecular
studies of protein expression was determined using Western blotting.

Specific Aim 2: To study combinatorial effects between AIT and SFN on antiinflammation
Anti-inflammatory effects of single and combined treatments between AIT-SFN, SFNLUT, AIT-LUT, and AIT-CUR were in vitro determined in lipopolysaccharide (LPS)-induced RAW

3

264.7 macrophage model. Molecular studies of protein expression, and inflammatory cytokines
were determined using Western blotting, and ELISA techniques, respectively.

Specific Aim 3: To study combinatorial effects between AIT and SFN on prevention of
chemical-induced oxidative damage
Cell viability was measured in RAW 264.7 macrophages pre-treated with AIT and SFN as
a single or a combined treatment before being exposed to an oxidant, tert-butyl hydroperoxide
(t-BHP). To investigate how bioactive compounds work together as antioxidants, cell viability,
intracellular ROS, total glutathione (GSH), cellular glutathione-S-transferase (GST) activity, as
well as the activation of key transcription factors (Nrf2, and NF-B), and phase 2 antioxidant
proteins were determined.
This study would have significant impact on an improvement of prevention and therapy
of cancer, and other diseases related to inflammation and oxidative stress. The knowledge from
this work will be fundamental for further bioactives and/or drug combination study and for
developing functional food to improve health benefits.
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CHAPTER 2
LITERATURE REVIEW

2.1 Overview of Cellular Oxidative Stress, Inflammation and Carcinogenesis
In cellular systems, oxidative stress can increase the production of inflammatory
mediators and initiate or promote carcinogenesis. Extensive studies have revealed the
mechanisms of oxidative stress, inflammation, and carcinogenesis as well as explanations of
how they are associated with one another. At the molecular level, key transcription factors such
as NF-B, Nrf2, and STAT3 are considered as linkers since they are found to be active during
these processes.

2.1.1 Oxidative Stress
Oxidative stress is an imbalance between a production of oxidants or reactive oxygen
species (ROS) and their eliminating factors known as antioxidants. Superoxide anion, hydroxyl
radicals, hydrogen peroxide, nitric oxide, and singlet oxygen are examples of ROS. Under normal
conditions, some of these ROS have functions in cell signaling and homeostasis. However, under
stresses, there is an overwhelming of ROS leading to damages of biomolecules such as DNA,
proteins, and lipids with potential influence on the whole organism (11).
Lipids, especially polyunsaturated fatty acids-containing multiple double bonds are
attractive to ROS. Free radicals such as hydroxyl radical are very reactive and not stable. They
obtain single electron from lipid molecule to make themselves more stable and generate
lipoperoxyl radicals which is an initiation of lipid peroxidation. During propagation, lipid radical
reacts with another free fatty acid, producing a different fatty acid radical and a lipid peroxide.
Malondialdehyde (MDA) which is a mutagen is also being generated during this process.
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Moreover, physiological properties of lipid-containing organelles such as cell membrane
integrity and permeability could be altered when lipids are modified (12, 13).
Similar to lipid peroxidation, when free radicals attack proteins, they generate radicals
on peptide molecules particularly on side chains of amino acids which can react with oxygen to
yield peroxyl radicals following with the consequences that change and end with MDA
production (14).
Free radicals, especially hydroxyl radical, can hydroxylate either a purine or a pyrimidine
base in DNA to generate radicals. 8- hydroxyguanine radicals made by an interaction between
hydroxyl radical and the base guanine could undergo further reactions, including a reaction with
oxygen, to generate a guanine peroxyl radical. Once the DNA base is damaged, a strand of DNA
breaks because hydrogen bond linking between bases can no longer occur. DNA damage is
harmful because DNA is a template for gene replication and transcription and thus protein
synthesis as a downstream process. It causes errors in signal transduction affecting cell functions
and causes mutations associated with carcinogenesis (15).
These are only examples showing how deleterious of oxidative stress is. In fact,
overwhelming ROS affect to other more biological molecules and the severity of the injury
depends on the type and concentration of particular ROS.

2.1.2 Inflammation
Inflammation is a physiological process of organisms to physical, chemical
or biological stimuli as an adaptive response to restore homeostasis. The controlled
inflammatory response is beneficial to the host. For example, it protects the host against tissue
irritation, injury, or infection. However, it can become unfavorable when it is dysregulated,
causing septic shock or leading to many disorders and diseases, such as cancers, metabolic
disorders, neurological disorders, cardiovascular diseases, and chronic inflammatory diseases
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(Figure 2.1). A successful acute inflammation eliminates infectious agents follow by tissue
repairing. If the acute inflammation is not successful to eliminate pathogen or any source of
tissue damage, including autoimmune disease or undegradable foreign bodies, the
inflammatory process persists and turn to a chronic inflammation.

Figure 2.1 Acute and chronic inflammation. Adapted from (16).

Inflammatory process composts of complex regulatory networks that includes inducers,
sensors, mediators, and effectors. The combination of each component determines the type of
inflammatory response. Inducers initiates inflammatory responses by activating specialized
sensors which then stimulate the production of specific mediators altering functionality of
tissue.
Inflammatory inducers can be exogenous and endogenous. Examples of exogenous
inducers are toxic compounds, foreign bodies, allergens, irritants, and microbes either
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pathogenic or non-pathogenic. Endogenous inducers are signals being produced by stressed,
damaged, and/or malfunctioning tissue.
Inflammatory mediators can be categorized into seven groups based on their
biochemical properties: vasoactive amines, vasoactive peptides, fragments of complement
components, lipid mediators, chemokines, cytokines, and proteolytic enzymes. Many mediators
not only affect their target tissues but also induce production of additional mediators.
Inflammatory effectors are cells and tissues that are specifically affected by the
inflammatory mediators. Responsiveness to certain mediators are varied. They have distinct
effects in different tissues and cell types as an adaptation to maintain homeostasis against
noxious conditions (17).

2.1.3 Carcinogenesis
Carcinogenesis is a process which normal cells are transformed into cancer cells. There
are three distinct steps in this process which are initiation, promotion, and progression.
Initiation happens when mutations occur in critical genes such as genes regulating cell
cycle checkpoints which are important in controlling proper cell division. When these genes are
mutated, cells lack an ability to detect malfunctions and pass through cell cycle or cell division,
carrying the mutations to the new cells. The results of the initiation step can be little or even no
observable changes in morphology of cells or tissues. It does not confer a permanent increase in
susceptibility to cancer formation.
Tumor promotion appears when there is disruption of non-mutagenic tissues by
wounding or inflammation. The result in non-malignant tumors, which may regress with no
further stimulus. It is an epigenetic process meaning a change in genetics that is not influenced
by DNA sequence manipulation.
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Tumor progression is a process transforming benign tumors to malignant tumors. There
are some further genetic mutations as well as tissue disruption involved. Without requiring
external stimuli, the mutated cells can generate angiogenesis to support an increase of size and
numbers of cells, resulting in a bigger tumor, a so-called tumor microenvironment composed of
multiple distinct cell types. Eventually, they can create capability for tissue invasion and
metastasis which is a distant development of secondary malignant tumor growth from the
primary site (18). These are also multiple steps beginning with the local tissue invasion, followed
by intravasation in which cancer cells invade through membranes of nearby blood and lymphatic
vessels. After that, the cancer cells escape from the lumina of both vessels to the parenchyma of
distant tissues (extravasation), form small nodules (micrometastases), and finally grow from
micrometastatic lesions to macroscopic tumors also known as colonization.
During the multi-step development of tumors, there are different hallmarks such as
sustaining proliferation signaling, evading growth suppressors, resisting cell death, enabling
replicative mortality, inducing angiogenesis and activating invasion and metastasis. These
hallmarks rationalize the complexities of neoplastic disease or cancer. These events are
underlined by genomic instability leading genetic diversity which in the end expedites their
acquisition and inflammation which fosters the functions of mentioned hallmarks.
Sustaining proliferative signaling is the most fundamental trait in cancer cells. They do
not have controls, as do the healthy cells and tissues do. In general, normal tissues control the
production and release of growth-promoting signals that instruct cells to the enter cell cycle
division through checkpoints in order to find and fix genetic mistakes if any or to send them to
apoptosis if the mistakes cannot be fixed. This is to ensure homeostasis of cell numbers and
maintain regular tissue functions. Unlike normal cells, cancer cells dysregulate these signals and
enable cell growth in sizes and numbers. Alternatively, cancer cells may send additional signals
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to normal cells within the supporting tumor-associated stroma to sustain more on various
growth factors. In addition, the receptors of these growth factors can be elevated in numbers
which increases chance of binding and rendering hyper responses without limitation.
Evading growth suppressors is another point which cancer cells must circumvent to
sustain cell proliferation. Tumor-associated protein p53 is a tumor suppressor that regulates
circuits governing decisions of cells to either proliferation or senescence activation and
apoptosis. It receives signal from stress and abnormality sensors functioning in the cells. If the
degree of genomic damage is excessive, p53 can call a pause to further cell cycle process until
the condition is normalized or it can trigger apoptosis in the case of non-fixable damage.
Therefore, dysregulation of p53 would support the result of cell proliferation increase.
Resisting cell death is a process that favors cancer development by regulating apoptosis.
There are two simple concepts for the regulation. First, the limitation of apoptosis happens with
the losing of p53 tumor suppressor that eliminates sensors of cell critical damage, thus mutated
cells are not sent to apoptosis machinery and survive. Alternatively, increasing of anti-apoptotic
proteins as well as their regulators expression by downregulating pro-apoptotic factors or by
short-circuiting the extrinsic ligand-induced death pathway support cancer development as well.
Enabling replication immortality can be achieved by extending telomeric DNA, which is a
region of repetitive sequences of nucleotide at each end of a chromosome. During chromosome
replication, enzymes that duplicate DNA cannot continue their duplication until reaching the
end of a chromosome, leading to more and more shortening of the chromosome in every
duplication. Telomere protects the end of the chromosome from deterioration including end-toend fusion with neighboring chromosome so cells can grow and pass through division cycles.
There is an association between telomere length and cancer risk. In cancer cells, long-length,
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repeating segments of telomere are added to the end of telomeric DNA by telomerase, which is
a specialized DNA polymerase and bring about unlimited replication potential of the cells.
Inducing angiogenesis happens in cancer cells during tumor progression. An “Angiogenic
switch” is activated almost all the time and remains constantly on, causing normally quiescent
vasculature to develop new vessels which help sustaining neoplastic growth. This is different
from normal cells where angiogenesis is transiently on only when necessary such as during
wound healing and reproductive cycling in females. Angiogenesis can be regulated by vascular
endothelial growth factor-A (VEGF-A) and thrombospodin-1 which are well-known prototypes of
angiogenesis inducers and inhibitors, respectively.
Activating invasion and metastasis are processes that promotes tumor progression.
Cancer cells develop changes in shapes and their attachment to other cells as well as to
extracellular matrix. Cancer cells lose the function of E-cadherin, which assembles epithelial cell
sheet and maintain the quiescence of cells within these sites. Therefore, cancer cells are
detached and capable to delocalize to distant target organ (1).

2.1.4 Association between Cellular Oxidative Stress, Inflammation, and Carcinogenesis
Oxidative stress has been implicated in many pathological conditions such as
cardiovascular diseases, neurological disorders, diabetes, and cancers. These diseases can be
classified into two groups. The first group is diseases involving mitochondrial oxidative stress,
which is caused by pro-oxidants shifting the thiol/disulfide redox state and impairing glucose. In
this case, the oxidative stress from overwhelming ROS can trigger an inflammatory response. By
contrast, the second group of diseases involves inflammatory oxidative conditions in which
inflammation contributes oxidative stress in cells. In the case of cancer, cellular condition
involving oxidative stress and inflammation may lead to cellular transformation from being
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normal to cancerous through continuous stimuli. One piece of evidence is redox imbalance in
cancer cells that contain higher ROS level than normal cells (12, 19).
Accumulating data support that tumors can originate at the sites of inflammation
(Figure 2.2), especially the chronic type that leads to cancer. For example, the development of
carcinomas in the gastrointestinal tract is attributed to Helicobacter pylori- induced gastric
inflammation. Patients suffering from inflammatory bowel diseases such as ulcerative colitis and
Crohn’s disease have higher risk to develop colorectal cancer. During inflammation, various
inflammatory innate immune cells generate ROS, which are chemical effectors in inflammationdriven carcinogenesis. Therefore, one of the possible mechanisms is that the generation of ROS
in inflamed tissues causes DNA damage and leads to activation of oncogenes and /or
inactivation of tumor suppressor genes.
Chronic inflammation is associated with all stages of carcinogenesis (initiation,
promotion, and progression). Their progressions are proceeded by remarkable molecular
players known as inflammatory mediators such as cytokines, chemokines, and regulators of
prostaglandins and nitric oxide production pathways.
Inflammatory cytokines can be soluble proteins secreted from cells to extracellular
space or they can be membrane-bound small proteins expressing as the immune response.
Cytokine signaling is initiated when cytokines bind to their cell-specific cognate receptors on cell
membrane followed by activation of intracellular kinases cascades with subsequent activation of
transcription factors predominantly STAT3, Nrf2, and NF-B which together regulate
physiological processes including oxidative stress, inflammation, and carcinogenesis.
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Figure 2.2 Involvement of inflammation in carcinogenesis. Adapted from (20).

Chemokines are soluble chemotactic cytokines, which are classified into four major
groups such as CXC, CC, XC, CX3C based on the positions of conserved cysteine residues. During
chronic inflammation, they are produced by pro-inflammatory cytokines. Chemokines have a
central role to recruit leukocytes at the site of inflammation. CXC and CC are common in tumor
cells with different selectivity for particular leukocytes. For example, both CXC and CC attract
lymphocytes. Only CXC attracts neutrophils. Similar to cytokines, chemokines also initiate their
signal by interacting with specific receptors. They involve in cell proliferation, invasion, and
metastasis of different tumors (21).
Regarding the association between inflammation and oxidative stress, there is an
accumulation of the ROS during inflammation which activates cellular survival signaling
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pathways including nuclear factor-B (NF-B) and the upstream kinase cascades which are
known to have crucial roles in inflammation, immunity, cell proliferation and apoptosis (11).
Under normal conditions, the transcription factor NF-B is inactive in a complex form with its
inhibitory molecule (IB) in the cytoplasm. However, it is activated during inflammation through
the phosphorylation process, which dissociates NF-B and IB from the NF-B - IB complex.
Phosphorylated-IB (p-IB) is subsequently ubiquitinated and degraded by proteasomes.
Activated NF-B translocates into the nucleus and upregulates the expression of numerous
target genes including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and
inflammatory cytokines (22, 23). The enzyme iNOS produces nitric oxide (NO) via the conversion
of arginine to citruline, in which excessive NO involves mutagenesis, tumerigenesis, and
carcinogenesis. Similarly, COX-2 catalyzes a specific step in biosynthesis of prostaglandins (PGs),
some of which, especially PGE2, are associated with cancer (24). Pro-inflammatory cytokines,
such as interleukin-1 (IL-1) and interleukin-6 (IL-6), also play key roles and are elevated in
inflammatory conditions (25). However, cells have phase 2 antioxidant and detoxification
proteins including heme oxygenase (HO)-1 regulated under the nuclear transcription factor
erythroid 2p45 - related factor2 (Nrf2) (26). This enzyme catalyzes degradation of proinflammatory free hemes and catalyzes the production of anti-inflammatory and antioxidant
molecules (27). NF-B does not only regulate inflammatory response, but also regulate
apoptosis. It has a dual role to either inhibit apoptosis through induction of survival genes
including B-cell lymphoma-extra large (BcL-xL) or to promote apoptosis when working along
with activator protein (AP-1) to induce expression of Fas ligand which belongs to the tumor
necrosis factor (TNF) family (28).
When ROS and inflammatory signals are continuously prolonged, disorders, including
carcinogenesis follow. In cancer cells, Signal transducer and activator of transcription3 (STAT3) is
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constitutively active due to the aberrant activity of the upstream signaling proteins of STAT3
such as endothelial growth factor receptor (EGFR), HER2, Src and JAK2. STAT3 activation is
linked to malignant cancer behaviors, including growth, epithelial-mesenchymal transition,
migration, invasion, metastasis and therapeutic resistance. In cell survival, STAT3 positively
upregulates survivin, B-cell lymphoma (Bcl)-2 and Bcl-xL which are anti-apoptotic proteins to
repress apoptosis (29, 30). In fact, apoptosis can be both negatively and positively regulated.
Another transcription factor, p53, is known to upregulate apoptosis upon the increase of its
expression through the downstream proteins such as cleaved caspase-3, and poly (ADP-ribose)
polymerase (PARP) (31). However, induction of STAT3 by expression of v-Src was shown to
suppress p53 levels resulting in more cell survival. The transcription factor p53 not only
regulated apoptotic event, but also cell cycle arrest. It could signal growth arrest of cell at a
checkpoint to allow DNA damage to be repaired before DNA replication or to lead cell arrest
before entering mitosis and undergo apoptosis when the damage was irreparable (31, 32). This
information reinforces on-going cancer when p53 is downregulated. During angiogenesis and
metastasis, STAT3 activation elevates expression of MMP-2, MMP-9 and VEGF. Matrix
metalloproteinase (MMP) carries metalloproteinase activity which plays a role to degrade
vascular basement membrane and of basic fibroblast growth factor, and VEGF, which are
important in vascular endothelial cell proliferation and facilitation of cell penetration through
extracellular matrix (33). Besides cell survival and tumor progression, STAT3 also regulates
inflammation. It has two different roles to upregulate either pro- or anti-inflammatory cytokines
depending on cellular conditions.
As mentioned, oxidative stress, inflammation, and carcinogenesis are regulated through
complicated networks. There are many transcription factors involved in a mechanistic pathway

15

and a transcription factor can control more than one pathway, suggesting association among
oxidative stress, inflammation, and cancer.

2.2 Possible Preventive and Therapeutic Mechanisms
Depending on the association among oxidative stress, inflammation and cancer,
changing at least one process could significantly affect the rest. Therefore, elimination of an
overwhelming ROS and prolonged inflammation could prevent initiation and promotion of
cancer. However, in the case of malignant tumors, increased ROS could lead to programed cell
death known as apoptosis. Decreasing inflammation would reduce angiogenesis thus tumor
growth is not accelerated (21). Consequently, the loop of sustained “inflammation-cancerinflammation” is no longer present. This information leads to a strategy to use combined
treatments to eliminate inflammation and to selectively regulate oxidative stress for cancer
prevent and therapy.

2.2.1 Antioxidation
Antioxidants act differently in the defense systems. The first level is preventive
antioxidants, which suppress formation of free radicals. For examples, glutathione peroxidase,
glutathione-S-transferase are known to decompose lipid hydroperoxides which are prone to
initiating radical formation. The second level is antioxidants that scavenge active radicals to
reduce ROS chain initiation and/or stop propagation reactions such as vitamin C and vitamin E.
The third level is the repair and de novo antioxidants, which include proteolytic enzymes in
cytoplasm and mitochondria. They recognize, degrade and remove oxidatively modified proteins
(34).
Based upon the source, antioxidants can be classified as endogenous and exogenous
agents (Table 2.1). Endogenous antioxidants include enzymatic and non-enzymatic molecules.

16

Table 2.1 Classification of antioxidants (Adapted from (35))

Classification

Antioxidant

Based upon their nature

- Enzymatic antioxidant: SOD, CAT, GPx, and GR
- Non-enzymatic antioxidant:
- Metabolic antioxidant: GSH, Lipoic acid, L-arginine,
Bilirubin, Metal-chelating proteins, Transferrin
- Nutrient antioxidant: Vitamin E, Vitamin C, Trace metals
(Selenium, Manganese, Zinc), Flavonoids, etc

Based upon source

- Endogenous antioxidant: Bilirubin, GSH, Lipoic acid, NADPH
and NADH, enzymes (SOD, CAT, GPx, GR)
- Dietary antioxidant: Vitamin C, Vitamin E, Carotenoids,
Polyphenols
- Metal binding protein: Albumin (Copper), Metallothionein
(Copper), Ferritin (Iron), Myoglobin (Iron), etc

Based upon mechanistic
action

- Catalytic systems to neutralize or divert ROS: SOD, CAT,
GPx
- Binding/inactivation of metal ions: Ferritin, Catechins, etc
- Self suicidal and chain breaking antioxidant: Vitamin C,
Vitamin E, GSH, Flavonoids

Superoxide dismutase (SOD), glutathione peroxidase (GPX), glutathione reductase (GR), catalase
(CAT), and heme oxygenase (HO) are the major antioxidants in the cells. SOD catalyzes
dismutation of superoxide anion into oxygen and hydrogen peroxide. There are three isoforms
of SOD in humans, which are cytosolic copper and zinc-containing SOD (Cu/Zn-SOD), manganese
requiring mitochondrial enzyme (Mn-SOD), and extracellular Cu/Zn-SOD (EC-SOD). GPX converts
a glutathione (GSH), a tripeptide-containing glutamate, cysteine, and glycine, to oxidized
glutathione known as glutathione disulfide (GSSG). During this process hydrogen peroxide and
lipid hydroperoxides are converted to water and corresponding stable alcohol, respectively. GPX
has isozymes in cytoplasm, mitochondria, and extracellular compartment. CAT also dismutates
hydrogen peroxide to water and oxygen. GR reduces GSSG to GSH as a recycling antioxidant
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system. HO catalyzes degradation of heme and generates carbon monoxide (CO), biliverdin, and
iron. HO and its product CO have a cytoprotective effect against oxidative stress. Two distinct
isoforms of HO are HO-1 and HO-2. HO-2 is constitutively expressed while HO-1 is inducible.
Endogenous non-enzymatic antioxidants such as glutathione, thioredoxin (Trx), and
melatonin are found in mammals. Glutathione, generally reduced form (GSH), is one of the key
antioxidants present in the body. It is ubiquitously expressed together with three other enzymes
which are GPX, glutathione-S-transferase (GST), and, GR. Trx system is composed of Trx and
thioredoxin reductase (TrxR). Trx is a disulfide-containing oxidoreductase that modulates redox
sensitivity of transcription factors. It can be found in cytoplasm, mitochondria, membrane, and
extracellular space. Reduced Trx has active dithiol groups which can scavenge ROS and maintain
proteins in their reduced states. After acting as an antioxidant, reduced Trx becomes oxidized
Trx which can then be reduced again by TrxR and NADPH. Melatonin is a hormone synthesized
from serotonin primarily in the pineal gland, but it is also produced in the retina, lymphocyte,
gastrointestinal tract, and bone marrow. It is ubiquitous and effective in both aqueous and lipid
phases to neutralize free radicals such as hydroxyl radicals, peroxyl radicals, superoxide anion,
and hypochlorous acid. Unlike other antioxidants, oxidized melatonin is irreversible and is
referred as a suicidal or terminal antioxidant.
As mentioned, regulation of ROS can also be achieved by modulating antioxidant
proteins. Potency of the endogenous antioxidants is regulated by specific transcription factor.
For example, Nrf2-Keap1 pathway responds to xenobiotics and eliminates oxidant. Nrf2 is a
transcription factor that modulates expression of genes coding for detoxification enzymes and
antioxidant proteins. Kelch-like ECH-associated protein or Keap-1 is a cysteine rich protein which
in its dimeric form interacts and sequesters Nrf2 in the cytoplasm, thus inhibiting transcriptional
activities. In response to attack by electrophiles, which can be ROS or any bioactive compounds,
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Nrf2 can be switched on and off via distinct mechanisms. Oxidative modification of Keap1 and
Nrf2 phosphorylation results in releasing of Nrf2 from Keap1. Free Nrf2 translocates into the
nucleus, binds to antioxidant responsive elements (AREs) involving activation of antioxidant and
detoxification gene expression, and results in cellular protection from free radical damage (36).
Vitamins, minerals and other bioactive compounds from fruits and vegetables are
examples of exogenous antioxidants. Ascorbic acid or vitamin C is a primary antioxidant in
plasma. It donates electrons to other molecules and protects them from oxidation. Vitamin E,
especially α-tocopherol, which is the most biologically active form, protects cell membrane from
lipid oxidation. It terminates the lipid oxidation process by donating an electron to scavenge
lipid peroxyl radical and becoming a less reactive radical which can be recycled to the reduced
form later on with the help of other antioxidants. However, α-tocopherol can also reduce iron
and copper which are pro-oxidants. Therefore, α-tocopherol has dual roles as either anti-or prooxidant, which varies case by case depending on the amount of α-tocopherol available to
scavenge ROS, as well as a reduction potential of α-tocopherol compared to other molecules
present in the system. Minerals including zinc (Zn), copper (Cu), manganese (Mn), iron (Fe), and
selenium (Se) are important elements of antioxidant enzymes by acting as cofactors such as Ferequiring catalase, Cu/Zn-SOD, Mn-SOD and Se-GPX. Plant bioactives such as polyphenols have
demonstrated for their antioxidant properties by different mechanisms including radical
scavenging, metal binding, upregulating expression of antioxidant proteins as well as increasing
antioxidant enzyme activities.

2.2.2 Anti-Inflammation
Because of the key role of the transcription factor NF-B in induction of proinflammatory genes, affecting various cells involved in immune response, NF-B has become an
attractive target to therapeutically control inflammation. Referring to the activation of NF-B
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pathway, inhibitory B (IB) would be phosphorylated by IB kinase (IKK) and free NF-B from
the NF-B - IB complex to translocate into the nucleus for upregulation of inflammatory
related genes, while IB in the cytoplasm is ubiquitinated and degraded by proteasomes. Since
NF-B pathway is composed of a number of discrete steps, different inhibitors, for which more
detail will follow, act differently with respect to their specific targets in the pathway.
IBα super-repressor is an IBα protein with mutations at serine residues 32 and 36.
This mutation leads to the incapability of the protein to be phosphorylated by IKK, providing a
consequence of not being degraded and retaining NF-B in the cytoplasm. In addition, this NFB repressor enhances the sensitivity of cells to apoptosis inducing stimuli. Therefore, no
prolonged inflammatory signal occurs.
Glucocorticoids inhibit NF-B pathway through diverse mechanisms. Prednisone and
dexamethasone are common ones that are widely used for their anti-inflammatory and
immunosuppressive properties. Dexamethasone induces expression of IB upon mRNA and
protein level to enhance the cytosolic retention of NF-B. However, there are other mechanisms
by which dexamethasone represses IL-6 expression and p65 NF-B-dependent transactivation
without changing IB protein level.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, sodium salicylate, and
sulfasalazine are used to treat chronic inflammation. Aspirin and sodium salicylate suppress IB
phosphorylation by inhibiting IB kinase (IKK) activity with inhibition of ATP binding to IKKβ.
Another related aminosalicylate derivative, mesalamine, prevents IL-1-mediated stimulation of
p65 phosphorylation. Thus, different NSAIDs inhibit NF-B pathway at multiple steps.
Immunosuppressive agents, including cyclosporine A and tacrolimus are used in organ
transplant to prevent graft-versus-host disease. They are non-competitive inhibitors of
chymotrypsin-like activity of the 20S proteasome. Therefore, they prevent IB degradation and
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inhibit NF-B from activation. They can also directly inhibit NF-B activity by modifying cysteine
residue in the activation loop of IKKβ.
Cyclopentenone prostaglandins induced by COX-2 are involved in the resolution phase
as regulators of inflammation and immune responses. They exert their anti-inflammatory
properties through the activation of peroxisome proliferator-activated receptor (PPAR)- which
is a member of nuclear receptor super family. Additionally, these PGs can directly inhibit NF-B.
One of the cyclopentenone PG metabolites, PGA1, inhibits TNF-α-induced phosphorylation of
IBα by inhibiting IKKβ activity with the cysteine residue modification, NF-B DNA binding, and
NF-B transactivation.
Peptide aldehydes such as MG101, MG132, and MG115 inhibit protease activity of
proteasome thus they prevent IB degradation and NF-B activation.
Natural products have biological activities to inhibit NF-B pathway. For example,
flavonoids, quercetin, and resveratrol downregulate NF-B, providing a consequence of fewer
downstream inflammatory mediators, including NO, and inflammatory cytokines.
A better understanding of the regulation of inflammation, including NF-B pathway may
provide opportunities to develop treatments. Although NF-B is currently an important target to
reduce an overwhelming inflammatory response, it may be not appropriate to block the NF-B
pathway for prolonged periods since it also plays a pivotal role to maintain host defense to
bacterial and pathogenic infection. However, short-term treatment might be necessary and
might also reduce side-effects (28, 37).

2.2.3 Anticancer
Studies of cancer hallmarks as well as their association with inflammatory signal and
oxidative stress have extended our understanding in biological complexity of cancer and bring us
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to develop treatments based on their mechanisms of action. This method promotes
development of drugs that have specific activities against a target while having relatively fewer
off-target effects.
It is widely accepted that cancer prevention is preferable to therapy. Therefore, it is
reasonable to redox balance with the help of antioxidants, not letting ROS overwhelm and cause
oxidative damages to biological molecules which is prone to cancer initiation. At the same time,
active carcinogens causing mutation can be detoxified by host phases 2 antioxidant and
detoxification enzymes such as glucuronidases, and sulfotransferases and excreted to the urine
(38). In addition, prolonged inflammation also generates ROS and links to cancer. Thus,
eliminating inflammation represent a valid strategy for cancer prevention as well as therapy. In
cancer therapy, there have been many cases facing adverse effects from using anticancer drugs
including toxicity to both tumors and host tissues, and toxicity arising from the accumulation of
the agent in a particular region such as the cardiovascular system and liver. These side effects
limit dose utilization and efficacy of the agent. Application of an anti-inflammatory agent with
anticancer drug can reduce this toxicity problem and enhance the therapeutic effects by acting
either additively, synergistically or sensitizing the conventional anticancer agent. For example,
combining celecoxib with docetaxel decreased hematologic toxicity in prostate cancer patient.
Other NSAIDs particularly aspirin may aid in preventing arterial thromboses, allowing an
anticancer agent to reach microscopic tumor foci more easily and improve the effect in the
patient. Although the anti-inflammatory agents do not change the pharmacokinetics of the
anticancer drug, they may affect its metabolism, leading to alterations in concentration, half-life,
and clearance of the active metabolites and consequently modify toxic doses and efficacy (39).
When a mutation occurs, cells have mechanisms to check and repair DNA damage
through cell cycle arrest. Cells with irreparable damage are sent to programmed cell death to
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terminate replication of genetic errors. Cells are shifted towards a more oxidizing environment
with higher ROS, leading to apoptosis and necrosis. Based on this nature of host to eliminate
cancer cells, a unique “oxidation therapy” was introduced. ROS generating enzymes such as
glucose oxidase and xanthine oxidase are directly delivered or induced in tumor tissue using
anticancer drugs fabricated with polymeric micelles or nanoparticles known as enhanced
permeability and retention-effect. Another approach is to decrease antioxidative systems in
tumors using inhibitors of antioxidant enzymes such as zinc protoporphyrin IX, an HO inhibitor.
Regarding ROS and cancer, it should be noted that different levels of oxidative stress affect
cancer differently. Low or intermediate level of oxidative stress cause DNA damage, mutation,
inflammation inducing carcinogenesis while high oxidative stress leads to programmed cell
death. Thus, it is practical to counter balance of cellular ROS to either prevent or to treat cancer
depending on stages of cells (38).
Furthermore, mechanism-based targeted therapies have promoted drug development
that can be classified regarding their effects on one or more hallmark capabilities. For example,
EGFR inhibitors, cyclin-dependent kinase inhibitors, pro-apoptotic mimetics, telomerase
inhibitors, inhibitors or VEGF signaling, and inhibitors of HGF/c-Met are used to treat against
sustaining proliferative signaling, evading growth suppressor, resisting cell death, enabling
replicative immortality, inducing angiogenesis, and activating invasion and metastasis,
respectively. However, it is also important to consider compensation pathways. Since each of
the core hallmark capabilities is regulated by partially redundant signaling pathways, inhibiting
at only one target is not enough. Furthermore, it cannot completely shut off the hallmark
capability, and initiates an adaptive response which causes resistance to the treatment.
Therefore, the design of treatment protocols to selectively co-target at multiple cores may
result in more effective therapy for human cancer (1).
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2.3 Dietary Bioactive Components Against Oxidative Stress, Inflammation and Cancer
Fruits, vegetables, and grains have beneficial effects against disorders and diseases
including cancer. These protective roles are mainly attributed to the presence of
phytochemicals. There are many types of phytochemicals including tannins, curcuminoids,
flavonoids, triterpenoids, steroids, saponins, and alkaloid. These bioactives possess a range of
biological activities whose mechanistic actions help in preventing and/or treating diseases (40).
The effectiveness of these compounds may result from their use in monotherapy or in
association with other compound(s) in combinations. The latter approach may provide an
optional strategy to enhance therapeutic efficacies against oxidative stress, inflammation, and
cancer.

2.3.1 Roles of Some Phytochemicals
Phytochemicals can reduce cancer risks by blocking initiation and suppressing later
stages, including promotion, progression, angiogenesis, invasion, and metastasis. Many of them
can alter metabolisms of procarcinogens to detoxify and excrete the toxic substances from the
body. Some of them have antioxidant activity to scavenge free radicals and reduce oxidative
stress. These efficacies in phytochemicals could prevent mutation which is an initiation stage of
cancer. Anti-inflammatory property of phytochemicals can also prevent tumor development.
They are sometimes used as a co-treatment to suppress or eliminate tumor cells with other
compounds possessing capabilities to inhibit growth by induction of cell cycle arrest and
apoptosis (41). Specific detail of particular phytochemicals (Table 2.2) will be followed.

2.3.1.1 Isothiocyanates
Isothiocyanates (ITCs) are a group of compounds found mostly in plants, principally cruciferous
vegetables such as broccoli, cabbage, and kale. Some marine sponges and fungi also
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Table 2.2 Chemical structures of selected phytochemicals

Phytochemical

IUPAC Name

Allyl
isothiocyanate

3-isothiocyanatoprop1-ene

Sulforaphane

1-isothiocyanato-4methylsulfinylbutane

Luteolin

2-(3,4dihydroxyphenyl)-5,7dihydroxychromen-4one

Curcumin

(1E,6E)-1,7-bis(4hydroxy-3methoxyphenyl)hepta1,6-diene-3,5-dione

Chemical Structure

have been reported to produce ITCs. In plants, ITCs are synthesized and stored as glucosinolates
(β-thioglucoside N-hydroxysulfates). When there are damages in plant tissues, glucosinolates
are released and converted to ITCs with the catalysis of myrosinase, an enzyme that coexists in
the plant but they are stored separately. Besides plants, gut microflora can also produce
myrosinase to hydrolyze glucosinolates from vegetable consumption. Glucoraphanin and
sinigrin are glucosinolates with different side chains that will be converted to sulforaphane (SFN)
and allyl isothiocyanate (AIT), respectively.
Previous studies showed that the amount of ITCs available most likely depended on
myrosinase activities in the vegetables. Since myrosinase is heat-labile, the bioavailability of ITCs
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from cooked broccoli is less than the amount of from fresh ones. In addition, intestinal
microflora myrosinase may only hydrolyze small fractions of glucosinolates ingested (42).
ITCs rapidly accumulate in all tested human and animal cells. They penetrate into a cell
by diffusion and quickly metabolized through the mecapturic acid pathway. Initially, there is a
conjugation with intracellular GSH, the most abundant thiols in the cell found to be a driving
force for ITCs accumulation. Glutathione-S-transferases (GSTs) enhance the accumulation by
promoting the conjugation reaction. Sequentially, the conjugates undergo enzymatic
modification to form cystenylglycine, cysteine, and N-acetylcysteine (NAC) conjugates. The level
of ITCs accumulation can reach millimolar concentration range before being rapidly exported at
least partly by membrane transporters including multidrug resistance associated protein-1
(MRP-1) in urine. Approximately, 72% of a single consumption of SFN was recovered in rat urine
as NAC conjugates in 24 hours and only 1% was detected in the second 24 hours (42, 43). Similar
to SFN, the bioavailability of AIT is high with nearly 90% of orally administered substance was
absorbed. The average concentration of AIT after 24-hour single consumption was 10 times
higher in urine in comparison to the concentration in blood (44). This information indicates that
both SFN and AIT can be quickly absorbed and urinary eliminated almost entirely within 24
hours after ITCs consumption.

2.3.1.1.1 Sulforaphane
Some cruciferous vegetables contain high content of a certain glucosinolate and the
corresponding ITC. For example, broccoli sprouts contain around 74% glucoraphanin of all
glucosinolates present in the sprouts. Relatively less or no detectable amount of indole and βhydroxyalkenyl glucosinolates that are associated with potential toxicities. In other words, SFN
can be particularly found in broccoli and broccoli sprouts in high levels. This is an important
information since some ITCs possess stronger effects than others.
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SFN exerts its protective effects through distinct mechanisms. One of them involves the
direct detoxification of carcinogens by inhibition of phase 1 enzymes of the cytochrome P450
system. Phase 1 enzymes occur when ligands bind to the aryl hydrocarbon receptors and the
complex is transported into the nucleus to bind the xenobiotic responsive element which is the
DNA region upstream of cytochrome P450 genes. This system usually relates to oxidation,
reduction, and hydrolysis which generally lead to xenobiotics detoxification, but are also
involved in the conversion of procarcinogens to carcinogens that can bind to critical molecules
including DNA. SFN inhibits some, but not all cytochrome P450 enzymes (CYPs) by different
mechanisms. For example, it is a competitive inhibitor of CYP2E1 in microsomes from livers of
acetone treated rats to inhibit genotoxicity of N-nitrosodiummethylamine. In human liver, SFN
decreases CYP3A4 mRNA, protein expression, and enzyme activity probably through xenobiotic
receptor without affecting CYP1A2. Therefore, SFN prevents formation of carcinogen-induced
DNA-adducts, which is an important step in blocking tumor initiation.
In addition, SFN is a potent inhibitor of heterocyclic amines which are mutagens derived
from cooked meat. Toxicity from 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine (PhIP), the
most abundant type of heterocyclic amines, can be significantly reduced with SFN treatment.
This protection was not attributed to modulation of CYP1A2 levels, but was ascribed to the
induction of phase 2 detoxification enzymes which convert carcinogens to inactive metabolites
that are readily excreted from the body thus preventing DNA damage. Phase 2 enzymes such as
glutathione S-transferases (GSTs), UDP glucuronosyltransferases and gamma-glutamylcystein
which is a rate-limiting enzyme in GSH synthesis, are induced via the binding of Nrf2 at
antioxidant responsive element (ARE). SFN increases phase 2 enzymes by reacting with specific
thiol groups on Keap-1 and form thionacyl adducts promoting dissociation of Nrf2 from Keap-1,
and allowing subsequent activation of ARE-driven genes. Notably, the induction of these
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carcinogen blocking genes by SFN is Nrf2 dependent. Without this transcription factor, the
upregulation of these genes are blunted.
Since Nrf2 regulates both detoxification and antioxidant genes, Nrf2 activation by SFN is
also indirectly involved in the elimination of ROS by enhancing the antioxidative cellular activity
of phase 2 antioxidant enzymes such as NAD(P)H quinone dehydrogenase (NQO-1), thioredoxin
(Trx) reductase and HO-1. Additionally, SFN induces antioxidant enzymes to counteract cellular
susceptibility to oxidative stress due to the decrease of cellular thiol groups, especially GSH,
from binding to SFN molecule itself.
Besides blocking mechanisms, SFN also has mechanisms to deal with post-initiation
stages of carcinogenesis by decreasing and/or eliminating tumors. It induces cell cycle arrest
predominantly at G2/M phase, but other phase arrest is possible as well, depending on the dose
and duration of SFN treatment. In human colon carcinoma Caco-2 cells, G2/M phase arrest were
observed with 20 µM SFN treatment, but higher concentration than that could induce
accumulation of sub-G1 cells and loss of mitochondrial membrane potential. In addition, p21
protein, a tumor suppressor that plays an important role in cell cycle arrest, was found to be
increased in expression with SFN treatment in both in vitro and in vivo.
Administration of SFN induced apoptosis as indicated by cleaved PARP. In colon cancer
cells HCT116, 15 µM SFN induced an activation of caspase-7, caspase-9, and apoptosisindependent p53, while it decreased the expression of B-cell lymphoma-extra large (Bcl-xL).
There was also a release of cytochrome C from mitochondria. In prostate cancer cells PC-3, the
induction of apoptosis was associated with caspase-3, caspase-7, and caspase-9 activation with
an increased Bax : Bcl-2 ratio. Correspondingly to the in vitro experiment, a PC-3 xenograft
experiment demonstrated that SFN administration in vivo could significantly inhibit tumor
growth by reducing tumor volume and weight, and increasing Bcl2-associated X (Bax) protein
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expression level. Therefore, it is clear that SFN induced apoptosis in prostate and colon cancers
through both death receptor and mitochondrial pathways.
SFN has also been implicated in the modification of histone acylation, a process
controlling gene expression at the chromatin structure, by inhibiting histone deacetylase
(HDAC). Increased HDAC expression and activity are common in many cancer malignancies. SFN
treatment in human embryonic kidney 293 cells and colon HCT116 decreased HDAC activity and
increased acetylated histones H3 and H4 in both cell lines. This HDAC inhibition was attributed
to SFN metabolites, SFN-cysteine, and SFN-NAC, which are generated after the conjugation of
SFN with GSH. In mice given a single oral dose of SFN or SFN-NAC, HDAC inhibition and p21
induction were observed with concomitant increased acetylated histones. Therefore, inhibition
of HDAC is associated with a SFN-mediated cell cycle arrest and apoptosis, which in turn limits
tumor growth.
As a “suppressing” agent of carcinogenesis, SFN also has anti-inflammatory properties
to decrease inflammatory mediators which are tumor promoting factors. SFN has been shown
to down-regulate at the transcriptional level lipopolysaccharide (LPS)-mediated induction of the
expression of iNOS, and COX-2 and the secretion of TNF-α in RAW 264.7 macrophage cells. The
activation of NF-B, the transcription factor in this inflammatory response, was found to be
decreased. SFN could either directly inactivate NF-B by binding to essential cysteine residues at
thiol groups or indirectly by interacting with GSH and/or other redox regulators such as Trx
which are relevant for NF-B function.
SFN exerts not only the direct effects on tumor cells, but also influence the growth of
established tumors by inhibiting angiogenesis and metastasis. In immortalized human
microvascular endothelial cells HMEC-1, SFN dose- and time-dependently inhibited hypoxiainduced mRNA expression of VEGF and angiogenesis associated transcription factors, hypoxia-
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inducible factor-1 alpha (HIF-1α) and c-Myc. It could affect the inhibition of basal membrane
integrity by reducing production of MMP-2 and reduction of cell proliferation, migration and
tube formation.
In summary, the anti-carcinogenic action of SFN is wide-ranging, involving detoxification
of carcinogens, an increase of cellular antioxidants, direct cytostatic action on tumor cells,
inhibition of angiogenesis, metastasis and inflammation (45-47).

2.3.1.1.2 Allyl Isothiocyanate
AIT, also known as mustard oil, is one of the most common naturally occurring ITCs. Its
parent compound, sinigrin, is particularly predominant in mustard, horseradish, and wasabi as
well as in commonly consumed vegetables such as Brussels sprouts, and cabbage. AIT is in liquid
form at ambient temperature with melting point at -80 °C. It has a very pungent taste due to its
activation of transient receptor potential A1 channel in sensory neurons. In plants, AIT serves as
a defense to repel herbivores. Sinigrin is mixed with plant myrosinase and converted to AIT as
the herbivores chew the plants.
AIT inhibits proliferation of various cancer cells with low IC50 values in the micromolar
range, even in drug resistant cells that overexpress drug transporter MRP-1 or Pgp-1. AIT
treatment is dose- and time-dependent. Interestingly, AIT is significantly less toxic to normal
cells. For example, 40 µM AIT exposure for 24 hours resulted in 36-38% human prostate cancer
cell survival whereas normal human prostate epithelial cells were viable as much as 83%
AIT has provided anticancer activities not only in cell cultures, but also in animal models.
In PC-3 xenografted mice, three times per week of AIT treatment (approximately 333 µmol/kg
body weight) inhibited tumor growth by approximately 45% with no apparent toxicity. Although
sinigrin was found four times more effective than AIT, both of them significantly reduced the
number of aberrant crypt foci in colonic mucosa of dimethylhydrazine-induced Wistar rats.
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AIT can inhibit cancer cell growth through induction of cell cycle arrest and apoptosis.
Similar to SFN, AIT could cause as high as 80% cell cycle arrest in either G1 phase or G2/M
phase. For example, human leukemia HL60 cells were arrested in G1 phase while bladder
cancer UM-UC-3 were arrested in G2/M phase.
The exposure of 10 µM AIT for 24 hours to HL60 cells induced nearly 30% apoptosis,
which was associated with disruption of mitochondrial transmembrane potential, activation of
several caspases, including caspase-3, caspase-8, caspase-9, and caspase-12, and activation of cJun N-terminal kinase (JNK). AIT also induced apoptosis in PC-3 cells, which was associated with
downregulation of anti-apoptotic Bcl-2 and Bcl-xL as well as an activation of extracellular signalregulated kinase and JNK. Nevertheless, AIT was not a good apoptosis inducer in some cancer
cells, such as HT29 cells and UM-UC-3 cells with less than 5% apoptotic cells found after
treatment which probably due to the dose of treatment.
Besides cell cycle arrest and apoptosis induction, AIT also influences the growth of
cancer cells by increasing histone acetylation. Its concentration at 20 µM was shown to
stimulate acetylation in mouse erythroleukemia DS19 cells without inhibiting histone
deacetylase, which is different from SFN that can inhibit the enzyme in cancer cells.
Both AIT and its NAC conjugate (AIT-NAC) at the concentration range between 0.1-5 µM
have been reported to significantly inhibit the transcription of MMP-2 and MMP-9 in human
hepatoma SK-Hep-1 cells which are associated with the inhibition of cell adhesion, migration
and invasion.
AIT also demonstrates its anti-inflammatory property by inhibiting NO and decreases
the expression of iNOS in LPS-induced J774.1 macrophage at concentrations less than 10 µM. In
HT29 colon cancer cells, higher AIT concentration between 25-100 µM could inhibit NF-B
activation, which was stimulated by LPS.
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In addition to mechanisms defending against tumor initiation, AIT has cytoprotective
properties through the induction of the cellular antioxidative system. AIT has been shown to
induce several phase 2 antioxidant and detoxification enzymes such as NQO-1, HO-1, and GST in
both in vitro and in vivo through Nrf2 activation.
Overall, AIT exhibits desirable attributes for cancer prevention and inhibition including
high bioavailability after oral administration, rapid uptake by cells, induction of the antioxidant
protective system, and specific cell toxicity in malignant cells than in normal cells. However, AIT
doses in the preclinical studies are far greater than the amount that normally people are
exposed to, raising the question whether dietary consumption of AIT could significantly
contribute to cancer prevention in human or should there be any strategy to make a benefit out
of dietary AIT. Therefore, further studies are necessary. So far, the most exposed to orally
administered AIT resulting from its specific elimination through the urine suggest that AIT may
be most useful for bladder cancer prevention (44).

2.3.1.2 Luteolin
Luteolin (LUT) is a flavone. It is one of the most common flavonoids found in many
plants in both aglycone and glycosides. Their dietary sources include celery, carrots, olive oil,
oregano, peppers, peppermint, rosemary, and thyme. These glycosides usually have sugar
moieties at positions 5, 7, 3’ and 4’, through one or several free hydroxyl (OH) groups on LUT
molecule. Scolymoside (LUT 7-O-rutinoside), and cynaroside (LUT 7-O-glucoside) are examples
of LUT 7-O-glycosides. Besides, O-glycosides, sugars can also be bound through a C-C bond.
Common C-glycosides of LUT are LUT-8-C-glucoside (orientin) and LUT 6-C-glucoside
(isoorientin) (8).
LUT has sufficiently high bioavailability and its metabolism is sufficiently low to allow
exertion of biological activities. LUT aglycone can be absorbed after oral administration and LUT
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7-O-beta-glucoside was also absorbed after being hydrolyzed to LUT by intestinal microbacteria.
LUT aglycone is converted to glucuronide, or sulfate-conjugates during passing through the
intestinal mucosa (48). It was passively absorbed more efficiently from the jejunum and
duodenum than from the colon and ileum. The plasma concentrations of LUT depends on the
form of LUT ingested. The free form of LUT was observed in human plasma after LUT
consumption. The plasma of rats orally administered LUT contained free LUT, and the
conjugation with glucuronide and sulfate of LUT and o-methyl LUT (diosmetin or chrysoeryol).
The maximum concentrations of LUT can be achieved in 1-2 hours after ingestion, and LUT
remains in the plasma for several hours before renal excretion as LUT conjugates(8, 49). In
addition, deglucuronidation of flavonoid glucuronides have been reported to occur in the large
intestine via bacterial β-glucuronidase, and aryl sulfatase. Plasma concentrations of luteolin
aglycone can be increased in some pathological processes such as inflammation according to
deglucuronidation of LUT monoglucuronide by stimulated neutrophils or certain injured cells
during this physiological condition(50).
In terms of toxicity, LUT has LD50 values of 411 mg/kg intraperitoneal injection in rats
and more than 180 mg/kg in mice. Oral administration in mice was determined with LD50 value
more than 2500 mg/kg (49).
LUT has been shown to possess a wide range of biological activities such as antioxidant,
anti-inflammatory, and anticancer activities. In comparison to the glycosides, LUT aglycone was
more effective according to the absorption rate.
Antioxidant properties of flavonoids are widely acknowledged from their structures. LUT
has a catechol group on B-ring and the presence of a C2-C3 double bond in conjugation with an
oxo group at C4 on the C-ring, which serve to donate hydrogen or electron to stabilize a radical
species, as well as to bind transition metal ions such as iron and copper. Besides, LUT can
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penetrate into the nuclei and reduce DNA damage induced by oxidative stress. In cell culture
studies, malondialdehyde production stimulated by tert-butyl hydroperoxide was reduced with
LUT treatment which its antioxidant potential was achieved through Nrf2/MAPK mediated HO-1
signaling cascade in RAW 264.7 cells (7).
LUT and its glycosides, as well as plants containing LUT have been shown to have antiinflammatory properties both in vitro and in vivo. Similar to their antioxidant properties, the
anti-inflammatory properties also associate with the ortho-dihydroxy groups at the B-ring and
OH substitution at C5 position on the A-ring (51). These compounds work by inhibiting activation
of NF-B and AP-1 transcription factors through different phosphorylation cascades proteins
and inflammatory cytokines, and result in downregulation of downstream proteins such as iNOS,
COX-2, and lipoxygenase (LOX). In LPS-induced murine macrophage, LUT inhibited Akt
phosphorylation, NF-B mediated gene expression, and the release of inflammatory cytokines
including TNF-α and IL-6. LUT also exerts its anti-inflammatory effects by blocking the activity of
HSP90 in macrophages (52). In animal studies, LUT inhibited arachidonic- or 12-Otetradecanoylphorbol-13-acetate (TPA)-induced ear edema (53). Pre-treatment with LUT oral
application also increased survival rate of mice being challenged with LPS by decreasing TNF-α
production, ICAM-1 expression in the liver and abolished leukocyte infiltration in the liver and
lung (8, 49). LUT can trigger changes of transcriptome in microglial cells under both conditions
with and without LPS, suggesting that it could be a promising agent to develop immunomodulatory and neuroprotective therapies for disorders relating to inflammation (54). These
anti-inflammatory properties of LUT may play important roles in cancer preventive activity of
this flavonoid.
Regarding cancer chemopreventive potential, topical application of LUT reduced tumor
incidence and multiplicity in either TPA or 7,12-dimethylbenzanthracene-induced skin
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papillomas in mice. Extract containing LUT in the drinking water enhanced a reduction in tumor
volume although no significant change in tumor incidence or multiplicity was observed. LUT, its
glycosides, and extracts containing these compounds demonstrated radioprotective effects by
reducing ROS and suppressing lipid oxidation. Several mechanisms have been revealed in the
cancer chemopreventive activity of LUT including inhibition of angiogenesis via inhibition of the
phosphatidylinositol 3'-kinase (PI3K) pathway in a murine xenograft model with VEGF-induced
angiogenesis. LUT can decrease the incidence of invasion and metastasis by inhibiting MMPs.
LUT can induce apoptosis in several cancer cell lines but not in normal human peripheral blood
mononuclear cells. Its anti-apoptosis has been associated with the ability to induce activation of
p53, to imbalance the Bcl-2 family of proteins, to promote STAT3 degradation by binding with
HSP90, and to inhibit fatty acid synthase activity. In addition, LUT significantly sensitized TNFinduced cell apoptosis via ROS accumulation which results in inhibiting NF-B and increasing
activation of JNK (8, 9).

2.3.1.3 Curcumin
Curcumin (CUR) or diferoylmethane is a polyphenol. It is a principal curcuminoid derived
from the rhizome of turmeric (Curcuma longa). It is soluble in acetone, dimethyl sulfoxide
(DMSO), or ethanol but not well soluble in water. CUR can exist in both bis-keto and enol forms.
The keto form, that acts as an H-atom donor, predominates in solid state as well as in acidic and
neutral solutions while the enol form predominates under alkaline conditions. CUR has
demonstrated ranges of therapeutic effects including antioxidant, anti-inflammatory and
anticancer properties. These activities are attributed to the chemistry of CUR molecule that
contains double conjugated bond in the side chain, two methoxy groups, two phenolic hydroxyl
groups, and central β-diketone moiety.
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Products from turmeric have been considered as safe by Food and Drug Administration
(FDA) in the USA, and Agricultural Organization/World Health Organization (FAO/WHO). A
clinical study showed that oral CUR consumption had no toxicity at a dose of 8 g/day for up to
18 months. However, the results could vary depending on the individual. Another study in
healthy volunteers orally intake 500-12,000 mg CUR showed that 7 out of 24 subjects developed
adverse effects including diarrhea, headaches, rashes, and yellowish stools. All toxicities were
grade 1 and no correlation with doses were observed.
CUR has low bioavailability in human due to its instability, low solubility, low absorption,
rapid metabolism through conjugation, and rapid elimination. In solution, CUR was found
degraded within 30 minutes to trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexanal,
vanillin, feruloylmethane, and ferulic acid. Corresponding to the poor absorption of the
molecule, low levels of CUR were found in plasma. A study in patients with pre-invasive
malignant or high-risk premalignant conditions showed that high dose daily CUR consumption
(8,000 mg) for three months provided a peak serum CUR as 1.75 µM in 1-2 hours after oral
intake and the level gradually declined in 12 hours. Majority of CUR oral consumption was
excreted in feces with 35% unchanged form, and the remaining 65% as CUR metabolites. In the
case of intravenous, and intraperitoneal administration of CUR in rats and mice, the
metabolites, mainly dihydrocurcumin, tetrahydrocurcumin, and hexahydrocurcumin were
derived from CUR before being converted to monoglucuronide conjugates, which were found
excreted in bile (55-58). A study of CUR metabolism from human and rat intestinal and hepatic
subcellular fraction demonstrated different results between the species. The extent of CUR
conjugation with sulfate and/or glucuronide was more in the intestinal fractions from humans
than those from rats, while the conjugation was less extensive in the liver fractions from
humans than those from rats (59).
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CUR can improve rheumatoid arthritis, psoriasis, inflammatory bowel disease,
postoperative inflammation, and inflammatory pseudo-tumors. The anti-inflammatory targets
of CUR include NOS, COX-2, chemokines, and pro-inflammatory cytokines such as IL-1, IL-2, IL-6,
IL-8, IL-12, and TNF-α, most likely through inactivation of the transcription factors, NF-B, and
AP-1, and p38 mitogen activated protein kinase (MAPK) depending on inflammatory inducers
and cell types (24, 56, 57).
Antioxidant properties of CUR are supported by its ability to directly scavenge ROS, as
well as the evidence that it increased in PPAR, GSH, HO-1, SOD, but it decreased ROS, and
inhibited LDL oxidation (56, 57). These properties are dependent on CUR concentrations and
chemical environments such as an availability of free Cu2+ ions. High concentrations of CUR were
shown to increase cellular ROS, which is one of the anti-proliferative mechanisms in cancer (55).
The anticancer properties of CUR have been demonstrated through the efficacy of the
molecule that can suppress proliferation, induce apoptosis in different cancer cell lines and
inhibit tumor formation in animal models of carcinogenesis. CUR multi-targets different
biological molecules including growth factors, cell receptors, transcription factors, and signaling
molecules in different pathways. For example, COX-2, EGFR, ERK1/2 and constitutively active
NF-B and IB kinase in pancreatic cancer were down-regulated by CUR. In vivo anticancer
properties confirm the in vitro studies. Intravenous administration of CUR liposome reduced
tumor size and decreased protein expression of CD31, VEGF, and IL-8 in murine xenograft
model. In many cases, CUR kills tumor cells without adverse effects on normal cells (55). In
azoxymethane-induced rat’s adenocarcinoma model, CUR orally fed by mixing with diet, dose
dependently inhibited the disease during tumor initiation, post-initiation and throughout the
promotion/progression stages by increasing apoptosis in the colon tumors (10).
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2.3.2 Combination of Dietary Bioactive Components as a Strategic Solution
Accumulating evidence suggests chemopreventive properties of dietary bioactive
components as well as other biological activities that they possess. Phytochemicals from foods
have received attention to prevent cancer and other diseases due to their few or no adverse
effects that are frequently found after long-term administration of pharmaceutical drugs (2).
Recently, studies have demonstrated specific combinations of phytochemicals that enhanced
biological activities more than using a single compound purified from fruits and vegetables
(Table 2.3). In fact, phytochemicals have also been combined with drugs to reduce drug toxicity
and enhance efficacy of treatments. Using multiple compounds in combinations could provide
antioxidative, anti-inflammatory, and chemopreventive improvements because different
compounds may target through different mechanistic pathways and offer a better result than
using one compound. This could lead to lower doses requirement thus reducing side effects and
minimizing the development of drug resistance (3).
ITCs, not only as a single treatment, but also as a co-treatment with other bioactive
compounds, have wide range of biological activities including anticancer, anti-inflammation and
antioxidant. In table 2.3, some studies emphasize enhanced biological activities when using
dietary bioactive components in combinations. Shen et al.(60) used the Apc Min/+ mouse model
to investigate a combination of SFN and dibenzoylmethane (DBM), an aromatic compound
found in licorice. In this experimental model, mice have a hereditary disease with an inactivation
of one allele of the adenomatous polyposis coli gene and prone to having multiple polyps in
their colon. Without removal, these polyps may eventually progress to colon cancer. The
combination treatment blocked the colon tumor development, while SFN and DBM alone
reduced tumor number by 80% and 60%, respectively. No statistical difference in the levels of
inflammatory mediators were found between tumor samples treated with the combination
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Table 2.3 The effects of the combination of phytochemicals

Compounds in
combination

Model of study

Effect

Sulforaphane and
Dibenzoylmethane

APCMin/+ mice

Sulforaphane and
3,3’Diindoylmethane

HCT116 colon cancer - Anti-proliferation
cells
- Increase of G2/M phase
cell cycle arrest

(61)

Sulforaphane and
Apigenin

Caco-2 colon cancer
cells

- Induction of phase 2 detoxification
enzyme, UDPglucuronosyltransferase (UGT1A1)

(62)

Sulforaphane and
Nobiletin

RAW 264.7
macrophages

- Anti-inflammation
- Decrease of iNOS and COX-2
expression
- Induction of HO-1 expression

(63)

Sulforaphane and
Curcumin

RAW 264.7
macrophages

- Anti-inflammation
- Reduction of inflammatory markers
including iNOS, COX-2, PGE2,
TNF, and IL-1
- Induction of phase 2 enzymes such
as HO-1, and NQO-1

Luteolin and
Celecoxib

MCF-7 and MDA-MB231 breast cancer
cells

- Anti-proliferation
- Increase of apoptotic cells
- Decrease of Akt phosphorylation

(65)

Luteolin and
Chicoric acid

RAW 264.7
macrophages

- Anti-inflammation
- Reduction of inflammatory markers
including NO, PGE2, iNOS,COX-2,
TNF-α, and IL-1β through
phosphorylation of NF-B and Akt

(66)

- Anti-tumor development with
significantly reduced number of
tumors

Reference

(60)

(64)

Sulforaphane and
Phenethyl
isothiocyanate
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Table 2.3 (Continued) The effects of the combination of phytochemicals

Compounds in
combination

Model of study

Effect

Reference

Luteolin and
Tangeritin

RAW 264.7
macrophages

- Anti-inflammation
- Reduction of inflammatory markers
including NO, PGE2, iNOS,COX-2,
IL-6, and IL-1β

(67)

Curcumin and
piperine

Oral administration in
rats and human

(68)

Patients with tropical
pancreatitis

- Increase of CUR bioavailability
without adverse effects
- Antioxidant properties by
decreasing MDA levels and
increasing GSH levels in
erythrocytes

Curcumin and
Quercetin

Patients with familial
adenomatous
polyposis

- Decrease of number and
size of polyps without
appreciable toxicity

(70)

Curcumin and
Phenethyl
isothiocyanate

Human PC-3 prostate
xenografts in
immunodeficient mice

- Reduction of the growth of PC-3
xenografts
- Inhibition of cell proliferation and
induction of apoptosis through
inhibition of Akt and nuclear factorκB signaling pathways

(71)

Curcumin and
Polyunsaturated
fatty acids

RAW 264.7
macrophages

- Anti-inflammation
- Reduction of inflammatory markers
including NO, PGE2, iNOS,COX-2,
5-LOX, and cPLA2
- Increase of an antioxidant enzyme,
HO-1

(72)

(69)

and the samples treated with individual component. However, both SFN and DBM alone as well
as their combination significantly decreased PGE2, leukotrieneB4, and expression of protein
markers of cell proliferation, suggesting both of them as potent dietary compounds for
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chemoprevention of gastrointestinal cancers. Another study using colon cancer cells also
demonstrated a synergy from using combination treatment. Pappa et al.(61) reported that the
incorporation of two glucosinolate products, sulforaphane and 3,3’-diindoylmethane, in HCT116
cells dose-dependently provided synergistic anti-cell proliferation by arresting cell cycle at G2/M
phase. At low doses, antagonism was observed, which was possibly due to low SFN doses (1-5
µM) that were very effective in inducing cell protective phase 2 detoxification enzymes.
Therefore, we should be aware of doses of utilization to avoid undesirable effects. Besides
inhibition of cancer cell and tumor growth, a combination treatment between SFN and apigenin
provided a synergistic induction of phase 2 detoxification enzyme UDP-glucuronosyltransferase
(UGT1A1) for cancer prevention. The synergy from apigenin and SFN was possibly due to
complementary effects from different mechanisms associating with NF-B translocation of the
two compounds (62). In addition, synergistic anti-inflammatory effects were also demonstrated
in the combined treatments between SFN and nobiletin (63), SFN and curcumin, and SFN and
phenethyl isothiocyanate (PEITC) (64). The combinatorial treatments decreased the release of
pro-inflammatory mediators (NO, PGE2, TNF, and IL-1), and the expression of inflammatory
proteins (iNOS, and COX-2), as well as increased the expression of phase 2 antioxidant enzymes
(HO-1 and NQO-1).
Besides the aforementioned studies on the combination of ITCs with some
phytochemicals, in vitro studies have exhibited the synergism between LUT and some other
compounds. In combination with celecoxib, LUT synergistically increased apoptosis in breast
cancer cells, especially in MDA-MB-231 cells, in which the combined treatment increased 50%
apoptotic cells in comparison to control after 72-hour treatment. The combined treatment also
decreased expression level of phosphorylated Akt, in which its activation plays a regulatory role
in pro-oncogenic pathways (65). LUT and chicoric acid in combination synergistically reduced
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inflammation in LPS-induced RAW 264.7 cells by decreasing cellular concentration of proinflammatory cytokines (TNF-α, and IL-1β), NO, PGE2, and inhibiting expression of iNOS and
COX-2. These anti-inflammatory potencies were regulated through the decreased level of
phosphorylated NF-B and the phosphorylated Akt (66). In addition, synergistic antiinflammation of LUT was observed when it was combined with tangeritin (67). This combination
decreased the level of NO, PGE2, IL-1β, and IL-6 released by LPS-activated RAW 264.7 cells. The
combined treatment also decreased mRNA and protein expression levels of iNOS and COX-2.
Some of the combinations such as CUR co-administered with piperine, which is an
alkaloid found in black pepper, orally administered in rats and healthy human volunteers
suggest an increase of bioavailability as much as 154%, and 2000%, respectively with no adverse
effect. The combination increased the serum concentration of CUR after ingestion, and
decreased CUR elimination (68). In addition, 500mg of CUR with 5mg of piperine enhanced
antioxidant activities in patients with tropical pancreatitis by reducing in the erythrocyte MDA
levels and increasing GSH levels although there was no corresponding improvement in pain (69).
Three times a day treatment of the combination of CUR and quercetin for 6 months significantly
decreased number and size of ileal and rectal adenomas in all 5 patients with familial
adenomatous polyposis without producing any appreciable toxicity (70). In immunodeficient
mice grafted with human PC-3 prostate, the combination of CUR with PEITC significantly
inhibited the growth of xenografts while the single treatment of PEITC and curcumin failed to
affect the growth of prostate tumor xenografts. The combined treatment increased apoptosis by
responding through caspase-3 and PARP. Reduced protein expression of p-Akt, p-GSK3βα, pBAD, p-IKKβα, and p-IκBα were closely correlated with the reduction of PC-3 tumor xenografts,
suggesting mechanistic pathways that CUR and PEITC are involved (71). In addition to the
anticancer and antioxidant properties, CUR combination with polyunsaturated fatty acids
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(docosahexaenoic acid or eicosapentaenoic acid) provided synergistic anti-inflammation in LPSinduced RAW 264.7 cells by decreasing NO, PGE2, as well as the proteins and mRNA levels of
iNOS, COX-2, 5-LOX, and cytosolic phospholipase A2 (cPLA2), and increasing HO-1 (72).
However, combination treatment does not only provide beneficial enhanced
therapeutic efficacies. Some adverse effects have been noted. For example, co-administration of
CUR and nonsteroidal anti-inflammatory drugs or anti-coagulant drugs may result in an increase
risks of bleeding (57).
A growing number of both in vivo and in vitro studies support enhanced biological
activities of combinations of dietary bioactives over a single compound utilization. Many of
them synergistically act together, suggesting why some foods demonstrate cancer
chemopreventive properties which cannot be explained based on an individual bioactive
ingredient. In fact, it is critical to understand how phytochemicals provide synergistic effects in
terms of both chemistry and biology. Therefore, further exploration of the mechanisms of action
would increase beneficial and reliable outcomes for the development of supplement regimens,
cancer prevention and therapies (41).
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CHAPTER 3
SYNERGISTIC CHEMOPREVENTIVE EFFECT OF ALLYL ISOTHIOCYANATE AND SULFORAPHANE
ON A549 NON-SMALL CELL LUNG CARCINOMA CELLS

3.1 Introduction
Lung cancer is one of the most common cancers. Although the rate of incidence and
death from lung and bronchus cancer has decreased in the past few decades, this type of cancer
had been estimated to be the number one cause of cancer death thus it is still a major health
problem in many parts of the world (73). Accumulating evidence suggests therapeutics based on
mechanisms of actions of cancers to appropriately control specific targets such as targeting
cancer stem cells, microenvironment, mutant kinases, etc (74, 75). However, there is another
strategy known as chemoprevention that could be effective to prevent cancer from being
initiated, promoted and/or progressed to the advanced malignant stages. Among
chemopreventive agents, natural compounds from fruits and vegetables are of interest due to
their multi-targeting activities, low toxicity, and low cost (76).
Isothiocyanates (ITCs) are well-known naturally occurring small molecules that are
produced by enzymatic conversion of glucosinolate precursors in cruciferous vegetables. ITCs
are suggested to be promising anticancer agents. Many of them including allyl isothiocyanate
(AIT) and sulforaphane (SFN) displayed anticarcinogenic activity through various mechanisms
including reducing activation of carcinogens, reducing cancer cell proliferation, inducing cell
cycle arrest leading to apoptosis, and decreasing invasion and metastasis (4, 5).
Combination of cancer chemopreventive agents is an alternative strategy that at least
two compounds may effectively act against cancer growth by synergistic type of interaction and
result in stronger effects compared to the result obtained by each compound individually (2).
Using multiple compounds in combinations could provide chemopreventive improvements and
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target through different mechanistic pathways offering a better result than using one
compound. This could lead to lower dose requirement thus reducing side effects and minimizing
the development of drug resistance (3). Several ITCs combinations have been tested on
different cancers by combining among themselves or with other anticancer agents, and
synergies have been observed on the basis of the combination index (CI) or relevant statistical
analyses (3). Gupta et al.(5) demonstrated that either benzyl- or phenyl ITCs can sensitize
platinum containing agents in lung cancer. However, the combined effects of ITCs, especially
AIT and SFN on carcinogenesis have not been well studied. Herein, we tested the hypothesis
that the combination of AIT and SFN produce a synergy in inhibiting the growth of human nonsmall cell lung cancer cells (A549). Therefore, we examined the effect of AIT and SFN
administered to cells individually in comparison to the mixture of them on cell survival and cell
migration. To determine pathways underlying the mechanisms of the combined treatment, we
investigated expression of protein markers associated with apoptosis, cell cycle arrest, cell
invasion and metastasis. We found significantly higher anticancer effects from using AIT-SFN in
combination rather than the individual compound against lung carcinogenesis.

3.2 Materials and Methods
3.2.1 Cells Culture and Treatments
Lung cancer A549 cells were purchased from American Type Culture Collection (ATCC,
Rockville, MD, USA), and were cultured in RPMI-1640 medium supplemented with 5% heatinactivated fetal bovine serum (FBS) and 100U/ml of penicillin and 0.1 mg/ml of streptomycin at
37°C with 5% CO2. Dimethyl sulfoxide (DMSO) at final concentration of 0.1 % v/v was used to
prepare cell treatments which are 2.5 - 12.5 µM AIT (98%, Sigma-Aldrich, St. Louis, MO, USA),
and 2 - 10 µM SFN (> 98 %, Qualityphytochemicals, Edison, NJ, USA). Cells were treated with

45

freshly prepared treatment in culture medium for 72 hours before subjecting to further analysis
as described below.

3.2.2 Measurement of Cell Viability
Cytotoxicity of AIT and SFN treatments on A549 cells were assessed by the enzymatic
reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; SigmaAldrich) as previously described (77) . Briefly, 2000 cells/well grown in 96-well tissue culture
plates were exposed to indicated series concentrations of AIT and SFN. After treatment, cells
were incubated for 1 hour with 0.5 mg/ml of MTT solution in cell culture medium and the
absorbance of resulting formazan product was measured at 570 nm using a microplate reader
(SpectraMax, Molecular Devices, Sunnyvale, CA, USA).

3.2.3 Detection of Apoptosis
Treated cells (4 x 104 cells/well in a 6-well plate) were washed with iced-cold phosphate
buffer saline (PBS) and detached using trypsin (0.25% trypsin-EDTA; Mediatech, Manassas, VA,
USA). Analysis of apoptosis by flow-cytometry (BD LSRII, BD Biosciences, San Jose, CA, USA) was
accessed using dual staining, Annexin V fluorescein isothiocyanate (Annexin V-FITC) and
propidium iodide (PI) in Annexin V binding buffer (BioVision, Milpitas, CA, USA) as previously
described (78). Annexin V-positive/PI-negative cells were identified as they are in early stage
apoptosis, while late apoptosis contains Annexin V-positive/PI-positive cells.

3.2.4 Cell-Cycle Analysis
Collected cells were fixed in 70% ethanol overnight at 4 °C. As previously described
(78), cells were suspended in PBS containing PI, and RNase (Sigma-Aldrich) in the dark for 30
minutes and analyzed on a flow cytometer. The population of cells in each cell-cycle phase was
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determined using BD LSRII flow cytometer (BD Biosciences), and data were processed using
ModFit LT software.

3.2.5 Examination of Intracellular ROS Accumulation
ROS in cells were monitored by a modified method from Wang et al.(79). Cells were
stained with 10 M 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma-Aldrich) in the
dark for 30 minutes followed by fluorescent detection using flow-cytometry. Fluorescent
intensity of DCFH dye uptaked relatively reflected intracellular ROS levels.

3.2.6 Cell Migration Assay
A wound healing assay adapted from Zhou et al.(80) was performed to observe cancer
cell migration. A549 (1.0×105 cells) were seeded in 24-well plate and were allowed to grow to a
confluent monolayer. Prior to scratch using a 200 µL- pipette tip, cells were washed with cold
PBS. Medium containing treatment was added to each well followed by gap-width
measurement using a transparent microscope (Eclipse TS100, Nikon, Melville, NY, USA) at the
beginning and the end of treatment (72 hours). For visual enhancement, cells were dyed with
crystal violet at the end of the treatment. Percent change in wound width reflected percent cells
migration.

3.2.7 Western Blotting
Whole cell lysates were prepared as previously described (78). Attached cells on the
culture plates were washed with cold PBS prior to the addition of RIPA buffer containing
protease and phosphatase inhibitors (Boston BioProducts, Ashland, MA, USA). Cells were
collected using cell scrapers into Eppendorf tubes and were placed on ice for 20 minutes. Cell
suspensions were then sonicated and lysed on ice for a further 20 minutes. Supernatants were
collected after centrifugation at 20,817 x g for 10 minutes and used to determine protein
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concentrations by bicinchoninic acid (BCA) protein assay. Equal amounts of proteins were
resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes (GVS Filter Technology, Indianapolis, IN). Blocking buffer in PBS was used to block
non-specific binding of antibodies prior to immunodetection using specific antibodies at the
manufacturer’s recommended concentrations. Protein bands were visualized on blots probing
with secondary antibodies using Odyssey system (LI-COR, Lincoln, NE, USA). Antibodies for
cleaved caspaes-3, caspase-3, cleaved PARP, PARP, Survivin, Bcl-xL, Cyclin B1, p21, STAT3 and
MMP-9 were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies for p53,
COX-2, and p-STAT3 were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). -Actin
antibody obtained from Sigma-Aldrich (St. Louis, MO, USA) was used as a loading control.

3.2.8 Analyses of Synergy
Synergistic effects of AIT-SFN combinations were analyzed based on Chou and Talalay’s
method (3) with modifications using R software. This model is used for constant ratio drug
combinations. When the combination dose of d1 and d2 provides the same effect x as Drug1
alone at dose Dx,1 and Drug2 alone at dose Dx,2, the combination index (equation 1) indicates
synergism, additivity, or antagonism of the combinatorial effect when the index <1, =1, or >1,
respectively.

Combination index = d1/Dx,1+ d2/Dx,2

(1)

The median-effect plot demonstrated by the equation 2 was used to find D value which
is the dose of a test compound that demonstrates the E effect. E is the fraction of cell survival in
this study while α is a slope parameter, and Dm presents the median effective dose of the
compound.
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log [E/(1-E)] = α(log D + log Dm)

(2)

3.2.9 Correlation Analysis
Pearson correlation analysis was performed to investigate the association between
different factors on the inhibition of cell proliferation related to oxidative stress after being
exposed to treatments. Correlations were considered significant when P value is less than 0.05.

3.2.10 Statistical Analysis
All cell culture experiments were repeated for at least three times with similar results .
Statistical comparisons were made using one-way analysis of variance (ANOVA) and P value of
less than 0.05 was considered significant.

3.3 Results
3.3.1 AIT-SFN Synergistically Reduced A549 Cell Viability
Using MTT assay, the effect of single compound of AIT and SFN on A549 lung cancer cell
viability was determined in comparison to their combined treatment with a constant ratio of
AIT:SFN at 1.25:1 based on their IC50 values which were 12.6 ± 1.2, and 10.3 ± 0.6 µM,
respectively. Figure 3.1A shows a concentration-dependent efficacy of both single and combined
treatments that they decreased cell viability after 72 hours. AIT (2.5 - 12.5 M) or SFN (2 - 10
M) alone decreased cell proliferation from 3.2% to 50.9% and from 4.2% to 49.9%,
respectively. Utilization of AIT and SFN co-treatment provided stronger anti-proliferation than
that of a single treatment, which is reflected by fewer viable cells and less concentration
requirement. Half-dose combination between AIT and SFN (6.25 M AIT with 5 M SFN)
provided as high as 58.6 % inhibition of cell viability. Based on Chou and Talalay’s method (3),
we further determined the mode of interaction between the two compounds by median-effect
plot and isobologram analyses. The median effect plot (Figure 3.1B) demonstrated reduced IC50
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Figure 3.1 Growth inhibitory effects of AIT, SFN, and their combined treatment on non-small
cell lung cancer A549. Cells were treated for 72 hours before viability measurement by MTT
assay. Data are shown as mean ± SD (n = 6). Combination indexes are shown in parentheses (A).
Median-effect plot (B) and isobologram analyses (C) of synergy between the combination of AIT
and SFN at different concentrations (1.25 µM AIT + 1 µM SFN, 2.5 µM LUT + 2 µM SFN, 3.75 µM
AIT + 3 µM SFN, 5 µM AIT + 4 µM SFN, and 6.25 µM AIT + 5 µM SFN) with in the ratio of 1.25:1
were constructed using Chou and Talalay’s method (3).

values of the combined treatments (5.53 ± 0.31 µM AIT and 4.43 ± 0.24 µM SFN) in comparison
to the IC50 values of each compound. Isobologram (Figure 3.1C) confirmed the synergistic effect
from the combined treatment with the combination index ranging from 0.82 – 0.94 (Figure
3.1A).
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3.3.2 AIT-SFN Synergistically Induced Cellular Apoptosis
Early and late apoptotic cells were relatively quantified by flow cytometry with Annexin
V/PI co-staining after 72-hour treatment. Figure 3.2A which are representative images of
Annexin-V/PI intensity dot plots of A549 cells, showed significantly increased dot intensity in Q2
(late apoptosis) and Q4 (early apoptosis) region and decreased dot intensity in Q3 region (nonapoptotic cells) in the AIT-SFN combined treatment group. Percent apoptotic cells were
obtained from the Annexin-V/PI dot plots. As shown in figure 3.2B, numbers of both early and
late apoptotic cells increased in dose-dependent manner under single and combined
treatments. Single treatment of AIT (12.5 µM) significantly increased numbers of early apoptotic
cells (8%) in comparison to control while the single treatment of SFN (10 µM) significantly
increased numbers of both early and late apoptotic cells by 8, and 13%, respectively.
Combination treatment, especially at higher concentrations clearly increased numbers of cells in
late-stage apoptosis over those in early-stage apoptosis. The increment of early apoptotic cells
under combination treatment stopped after reaching 15% as the highest concentrations of the
combined treatment did not increase apoptotic cells in comparison to the milder combined
treatments. However, the number of late apoptotic cells as well as total apoptotic cells under
the combination treatments were dose-dependent. A synergy in total apoptosis (CI = 0.61-0.79)
was observed at as low doses as 6.25 M AIT with 5 M SFN that could increase 34% total
apoptotic cells. The higher combined doses (12.5 M AIT with 10 M SFN) increased more
apoptotic cells to 52% in total in comparison to control without treatment.
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Figure 3.2 Effect of AIT, SFN, and their combination on apoptosis. Cells were treated for 72
hours, followed by apoptosis measurement with flow cytometry after Annexin-V/PI co-staining.
(A) Representative images of Annexin-V/PI intensity dot plots of A549 cells showed significantly
increased dot intensity in Q2 (late apoptosis) and Q4 (early apoptosis) region and decreased dot
intensity in Q3 region (non-apoptotic cells) in the AIT-SFN combined treatment group. (B)
Percent apoptotic cells were calculated from the Annexin-V/PI dot plots. Results are presented
as mean ± SD (n = 3; *P < 0.05). Combination index (CI) ± SE are in parentheses. (C) Expression of
relating proteins were monitored by Western Blotting. The protein band intensities underneath
the blots were quantified using Image Studio software. β-Actin served as an internal loading
control. The results are representative of 3 experiments.
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To further elucidate the molecular basis for this event, expression of proteins associated with
apoptosis pathways was compared through immunoblotting. As shown in Figure 3.2C, both
single and combined treatment dose-dependently decreased expression of survivin, an antiapoptotic protein, and increased expression level of pro-apoptotic proteins which are p53,
cleaved caspase-3, and cleaved PARP. The highest concentrations of the combined treatment at
12.5 M AIT with 10 M SFN, obviously increased expression of pro-apoptotic proteins,
especially cleaved PARP that were 70.5-fold increased while the expression of PARP did not
change much, suggesting the abundance of PARP in cells. The expression of cleaved caspase-3
was 6.5-fold increased with a correspondingly decreased of the expression of caspase-3 at the
highest combinatorial concentration, suggesting a conversion of caspase-3 to cleaved caspase-3.
In addition, Bcl-xL which is a member of Bcl-2 family known as an anti-apoptotic regulator also
had relatively constant expression under treatments compared to the control. The results of
pro- and anti-apoptotic proteins expression were consistent with Annexin V/PI co-staining
analysis that demonstrates enhanced apoptotic effects from the combined treatment. The
results suggested that the combination of AIT and SFN improved the anti-proliferation of A549
lung cancer cells through increasing number of apoptotic cells, especially at the late-stage
apoptosis.

3.3.3 AIT-SFN Significantly Induced G2/M Cell Cycle Arrest
To gain further insight into the mechanism of their anti-proliferative activities, A549
cells were treated with either AIT (3.125, 6.25, 12.5 μM), or SFN (2.5, 5, 10 μM) alone or in
combination, and their effect on cell cycle progression and distributions were assessed after 72hour treatment. In figure 3.3A, representative images of A549 cell cycle histogram showed
significantly increased G2/M phase arrest in the AIT-SFN combined treatment group. Percent
cells population in each phase were calculated from the cell cycle histogram. As shown in Figure
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3.3B, in comparison to control, there was no major phase-specific change in cell-cycle
progression under any single treatment at the concentrations lower than 12.5 μM and 10 μM
for AIT, and SFN, respectively. At these high concentrations, AIT decreased G0/G1 cell
population but did not significantly change cell population of the other phases while SFN

Figure 3.3 Effect of AIT, SFN, and their combination on cell cycle after 72-hour treatments. Cells
were fixed with ethanol, treated with RNAse and PI before determining cell cycle progression by
flow cytometry. (A) Representative images of A549 cell cycle histogram showed significantly
increased G2/M phase arrest in the AIT-SFN combined treatment group. (B) Percent cells population
in each phase were calculated from the cell cycle histogram. Results are presented as mean ± SD (n
= 3; *P < 0.05). (C) Expression of cyclin B1 and p21 which relates to G2/M phase arrest were
determined using Western Blotting. The protein band intensities underneath the blots were
quantified using Image Studio software. β-Actin served as an internal loading control.
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significantly increased G2/M phase arrest with a decrease in S-phase population. AIT and SFN
combined treatment at concentrations of 12.5 and 10 μM, respectively significantly increased
G2/M phase arrest with up to 47% and lowered G0/G1 population to 37%. However, the
combination treatment under the concentration used in this study did not show any synergy on
G2/M phase arrest of A549 cell population. Although there was no synergy from the combined
treatment on the result of cell cycle arrest, protein expression of p21 (Figure 3.3C) which is a
G2/M phase negative regulator was increased in dose-dependent pattern with the maximum at
5-fold under high-dose combined treatment (12.5 μM AIT with 10 μM SFN). An opposite trend
was observed in the expression of cyclin B1, which is necessary during G2/M phase of cell cycle.
Decreased expression of this protein (9-fold lower than control) increased G2/M phase of cell
arrest. The results of protein expression corresponded to the flow cytometry analysis of PIstained cells that combination treatment of AIT and SFN increased G2/M phase arrest in A549
cells.

3.3.4 AIT-SFN Significantly Increased Cellular Oxidative Stress
Cellular oxidative stress, was assayed in DCFH-DA-stainned A549 cells after 72-hour
treatment using flow cytometry (Figure 3.4). ROS was monitored only in the population of livedcells due to non-stainable property of dead cells. There was a significant increase of ROS levels
in A549 treated with combined treatment. The concentrations of 6.25 M AIT with 5 M SFN,
and 12.5 M AIT with 10 M SFN increased ROS 1.9-, and 2.9-fold, respectively. Combined
treatment at lower concentrations than those indicated doses as well as single treatment (as
high dose as 12.5 M AIT or 10 M SFN) did not significantly change ROS in A549 cells in
comparison to control.
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Figure 3.4 Effect of AIT, SFN, and their
combination on cellular ROS. A549 cells
were incubated with the indicated
treatments for 72 hours and stained with
DCFH-DA before detection by flow
cytometry. Results are presented as mean
± SD (n = 3; *P < 0.05).

Considering correlation analysis (Table 1) between ROS level in A549 and either
apoptosis or cell cycle arrest that was constructed based on Pearson correlation, there was a
significantly strong positive correlation between intracellular ROS and apoptosis, especially the
late apoptosis as well as a correlation between ROS and G2/M phase cell arrest. Slightly less
correlation was observed between ROS and early apoptosis. A Negative correlation was found
between ROS and G0/G1 phase arrest while no significant correlation was observed between
ROS and S phase of cells. The correlation analysis confirmed the consistency of results and
suggested that apoptosis and G2/M phase arrest under combined treatment were mediated
through ROS signaling.

3.3.5 AIT-SFN Synergistically Inhibited Cell Migration
The inhibitory effect of AIT and SFN on migration of A549 cells through wound healing
assay was examined by comparing the wound width right after treatment application in
comparison to the wound width after 72-hour treatment. Figure 3.5A shows representative
images taken at hour-0 in comparison to hour-72 using 4× magnification. When A549 cells were
incubated with AIT and SFN in either single or combined treatment, the cell migration was
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Table 3.1 Correlation analysis of oxidative stress and apoptosis or cell cycle arrest

Factor

Pearson’s
correlation
coefficient

P value

early apoptosis

0.795

0.006

late apoptosis

0.957

< 0.001

total apoptosis

0.932

< 0.001

G0/G1 phase

-0.757

0.011

S phase

-0.558

0.93

G2/M phase

0.810

0.004

inhibited in a dose-dependent manner (Figure 3.5B). Treatment of AIT at the concentrations of
6.25, and 12.5 M significantly decreased wound healing by 13, and 22%, respectively. SFN at 10
M also significantly decreased wound healing by 26%. Furthermore, the synergy from AIT-SFN
combined treatment was obtained started at as low dose as 3.125 M AIT with 2.5 M SFN. The
maximal anti-cell migration effect from the highest combinatorial concentrations (12.5 M AIT
with 10 M SFN) used in this study was 48% with the interaction index of 0.59. After studying
cell migration which is an integral part of metastasis, we further examined expression of
proteins that play important roles in lung cancer metastasis including COX-2, p-STAT3 and MMP9 by Western blotting. Treatment of AIT or SFN alone in A549 cells reduced the expression levels
of COX-2 and p-STAT3 in a dose-dependent manner as compared to the expression of untreated
control. Low concentration of SFN at 5 M and its half-dose combination (2.5 M SFN with
3.125 M AIT) slightly increased MMP-9 expression by 0.5-fold while higher concentrations of
AIT, SFN, and their combinations provided an opposite effect. The results from Western blotting
were consistent with that observed from cell migration assay that combination treatment
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between AIT and SFN, especially at higher concentrations improved anti-metastatic property in
A549 lung cancer cells.

Figure 3.5 Effect of AIT, SFN, and their combination on cell migration after 72-hour
treatments. (A) Representative images taken at hour-0 in comparison to hour-72 using 4×
magnification showed significant inhibitory wound healing by the combination treatment. (B)
Percent wound healing was calculated from width of the wound. Results are presented as mean
± SD (n = 4; *P < 0.05). (C) Expression of proteins related to cell migration were determined
using Western Blotting. The protein band intensities underneath the blots were quantified using
Image Studio software. β-Actin served as an internal loading control.

3.4 Discussion
This study has demonstrated for the first time the synergistic effect of two bioactives,
ITC type of compounds, which are AIT and SFN on A549 chemopreventive properties. First, we
determined the anti-proliferative potential of AIT and SFN alone in non-small cell lung cancer
A549. IC50 values after 72-hour treatment of AIT and SFN were 12.64  1.19, and 10.29  0.66
µM, respectively, suggesting that SFN slightly had higher efficacy than AIT to inhibit A549 cell
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growth. Corresponding to our results, SFN also had lower IC50 doses than AIT in inhibiting growth
of 8226/S myeloma and HepG2 cells after being treated for 3 days (81). In addition, the
cytotoxic effects of ITCs are selective. AIT and SFN did not demonstrate toxicity in non-malignant
cells at the concentrations that could inhibit growth of cancers (44, 82). Furthermore, they have
been shown to possess antioxidant properties in healthy cells by lowering ROS through phase II
detoxification proteins (83-85).
Based on the IC50 values of AIT and SFN on A549 growth inhibition, a combination of AIT
and SFN at ratio of 1.25:1 was used in comparison to the single treatment. Our analysis using
Chou and Talalay’s model (3) displayed similar degree of synergism with the combination index
ranging from 0.82 – 0.94 over concentrations varied in this study. Through combination index
analyses, AIT and SFN combined treatment exhibited synergism by lowering concentrations of
AIT and SFN 2 - 2.9-fold compared to the results of each compound. This moderate to slight
interaction is possibly due to characteristics of natural compounds that are multi-targeting but
milder in comparison to pharmaceutical drugs. Supporting evidence showed that the majority of
natural compounds in combination provided 2 - 10 fold anticancer improvement (86). As being
shown in figure 3.1, the mixture of both AIT and SFN present together for 72 hours
synergistically inhibited growth of A549 cells. On the contrary, the combined treatment with
one compound presented at a time (either 36-hour AIT followed by 36-hour SFN or SFN followed
by AIT) did not demonstrate any synergy (data not shown). These data suggested that both
compounds needed to be applied at the same time to allow enhancement of chemopreventive
effect of these two ITCs.
We further demonstrated that the combination of AIT and SFN synergistically increase
apoptotic cells, particularly in late apoptosis. When comparing the values of combination index
obtained from cell survival MTT assay and the values obtained from flow cytometric apoptosis
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assay, we found a stronger synergy from anti-apoptotic activity (CI = 0.61  0.03) in comparison
to the anti-proliferative activity of A549 cells (CI = 0.82  0.02) using MTT assay. This information
suggested that AIT and SFN in combination played important roles in controlling cell growth at
least through apoptosis pathway. However, there are other factors such as cell cycle arrest,
necrosis, autophagy, as well as phase II detoxification system that might also affect the overall
efficacy of the treatments on A549 cell survival. The validity of this result was demonstrated by
Western Blotting, in which treatments clearly increased pro-apoptotic proteins and decreased
one of the anti-apoptotic proteins expression. A transcription factor, p53, is known to regulate
apoptosis upon the increase of its expression through the activation of downstream proteins
such as caspase-3, PARP, Bcl-xL, and survivin (31). ITCs both single and combined treatments
dose-dependently increase the expression of p53 and other pro-apoptotic proteins. The increase
of p53 led to an obvious decrease of the inactive form caspase-3 and to increase expression of
the active cleaved caspase-3 under combination treatment at high concentrations. PARP which
had dual role in both DNA repair and apoptosis relatively expressed at constant levels under all
treatments. Corresponding with the expression of cleaved caspase-3, cleaved PARP was also
induced by the combination treatment. On the other hand, expression of survivin, an antiapoptotic protein inhibiting caspases (87), were decreased, especially by the high-dose
combination. Although the expression of Bcl-xL remained relatively constant, the overall
comparative amounts of pro- and anti-apoptotic proteins defined whether the cell will undergo
cell death. As has been demonstrated here, the expression of three pro-apoptotic proteins were
increased and one anti-apoptotic proteins was decreased by our treatments. In this case, the
expression of these pro- and anti-apoptotic proteins corresponded with percent cells in
apoptosis and suggested that ITC treatments induced apoptosis through p53 transcription factor
and some of its downstream proteins including cleaved-caspase3, cleaved-PARP, and survivin.
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Correspondingly, p53 expression not only regulated apoptotic event but also led to an
effect on cell cycle arrest. The transcription factor p53 could signal growth arrest of cell at a
checkpoint to allow DNA damage to be repaired before DNA replication or to lead cell arrest
before entering mitosis and undergo apoptosis when the damage was irreparable (31, 32). Our
results demonstrated a trend of cells in G2/M phase increase under both single and combined
treatments upon dose increment, particularly the high-dose combination that significantly
increased cells in G2/M phase and decreased cells in G0/G1 phase. Although there was no
synergy obtained on G2/M phase arrest, the data corresponded to the previous experiment that
the combination of 12.5 µM AIT with 10 µM SFN could synergistically induce apoptosis. Taking
these data together, the combination treatment once reaching certain concentration at the
ratio used in this study possibly induced DNA damage as being indicated in several studies(5, 88,
89), and led to cell cycle arrest at G2/M phase and apoptosis. At the molecular level, this was
accompanied with the efficient inhibition of the expression of cyclin B1, a regulatory protein in
mitosis while a protein marker of G1 phase (cyclin D1), and a marker of S phase (cyclin E) were
increased (data not shown). In addition, p21 which is one of the inhibitors of cyclin-dependent
kinase that regulates cells mitosis phase, was also increased in expression.
The increase of intracellular ROS under AIT and SFN combination treatment was
correlated with cell cycle arrest and apoptosis. Single treatment did not significantly affect the
ROS level possibly corresponding to their low doses. This information was consistent with other
studies using SFN and other ITCs on many cancer cell lines including lung cancer (90-93). These
data indicated that high doses of isothiocyanates could increase ROS and depleted reduced
glutathione leading to cell cycle arrest and apoptosis induction. Therefore, through ROS
generation causing DNA damage, the combination of AIT and SFN mediated G2/M phase cell
cycle arrest and late apoptosis.
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Apart from cell viability, cell migration was also observed under treatments as an
indicator of anti-metastatic/invasive property. Our results showed that A549 migration was
significantly and synergistically delayed when the AIT and SFN were combined and used to treat
A549. The higher concentrations of the combination treatment demonstrated a stronger
synergy by lowering the combination index values. Based on doses of treatments used in this
cell migration experiment, which is under the same range of those being used in cell viability
experiment, compounds toxicity could play a role in retarding cell migration. However,
expression of COX-2 was decreased by AIT and SFN, especially when they are combined
together. Reducing COX-2 expression could lower the level of prostaglandin E2 (PGE2)
production, leading to less promotion of tumor growth due to PGE2 activating pathways that
control cell proliferation, migration, apoptosis, and/or angiogenesis (94). Besides COX-2, STAT3
also regulates the expression of various genes involving proliferation, apoptosis, angiogenesis,
invasion, and metastasis (29, 30). Here, we showed that the combination treatment clearly
decreased phosphorylated STAT3, an active form, as well as MMP-9 which had a function in
metastatsis to facilitate cells penetration through extracellular matrix (33).
Our findings show that the combined treatment of ITCs particularly AIT and SFN
synergistically acted as chemopreventive agents in the inhibition of cancer proliferation and
progression. These synergistic effects could be due to the fact of low doses of compounds
utilization which could minimize the development of drug resistance (3). The use of more than
one compound as a treatment may also act through different mechanisms and provide an
efficient outcome. However, more information is still necessary for a better understanding in
the mechanistic actions behind the synergy of compounds in combination. Additionally, the
concentration ranges of AIT (1.25 - 12.5 µM) and SFN (1 - 10 µM) used throughout this study
were reasonable in comparison to the concentration of AIT and SFN found in blood of rats and
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mice after oral application of the compounds (44, 95). This suggests a high possibility to obtain
similar synergy in an in vivo model as well.
In summary, the present study has provided evidence supporting potential of the
combined treatment of AIT and SFN that they synergistically multi-targeted the system of
proliferation and metastasis of A549 non-small cell lung cancer cells. We have also
demonstrated cell cycle arrest and apoptosis mediated by the treatments through intracellular
ROS signaling. These results demonstrate the synergy from AIT and SFN combined treatment
that can be useful for further in vivo and clinical studies as well as being a guidance to prevent
lung cancer.
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CHAPTER 4
SYNERGISTIC ANTI-INFLAMMATORY EFFECTS OF ALLYL ISOTHIOCYANATE AND
SULFORAPHANE COMBINED BETWEEN THEMSELVES AND WITH OTHER NATURAL BIOACTIVES

4.1 Introduction
Inflammation can be categorized as both acute and chronic. A regulated inflammatory
response known as acute inflammation is beneficial in the inducing wound repair and in acting
against irritants including microbial infections. On the other hand, dysregulation of the
inflammatory response can induce chronic inflammation leading to many disorders and
diseases, such as neurodegenerative diseases, cardiovascular diseases and cancers (17).
During inflammation, many biological events happen including an increased uptake of
oxygen, which leads to an accumulation of reactive oxygen species (ROS), as well as an
activation of cellular survival signaling pathways such as nuclear factor-B (NF-B), as well as the
mitogen-activated protein kinases (MAPKs), extracellular signal–regulated kinase, (ERK), p38,
and c-Jun N-terminal kinase (JNK), which are known to have crucial roles in inflammation,
immunity, cell proliferation and apoptosis (11). Activated NF-B translocates into the nucleus
and upregulates expression of numerous target genes including inducible nitric oxide synthase
(iNOS), cycloxygenase-2 (COX-2), and inflammatory cytokines (22, 23). iNOS produces nitric
oxide (NO), in which its excessive amount involves mutagenesis, tumerigenesis, and
carcinogenesis. Similarly, COX-2 catalyzes biosynthesis of prostaglandins (PGs), which some of
them, especially PGE2, are associated with cancer (24). Inflammatory cytokines, such as
interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) are also elevated under
inflammatory conditions (25). Besides, cellular heme oxygenase-1 (HO-1) regulated under the
nuclear transcription factor erythroid 2p45 - related factor2 (Nrf2), has antioxidant property by
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catalyzing degradation of pro-inflammatory free hemes and production of anti-inflammatory
molecules (26, 27).
Although many bioactive compounds have been found to contribute anti-inflammatory
properties, the information on utilizing these compounds in combinations to increase the
efficacy of the therapeutic effects has been limited. Moreover, there has been a considerable
amount of evidence suggesting the beneficial effects to combination treatment in decreasing
the risk of toxic side-effects due to too high dose administration and also to reduce the
development of treatment resistance (3, 63, 66, 67, 96).
This study investigated the anti-inflammatory effects of the combination between
sulforaphane (SFN) and allyl isothiocyanate (AIT), which are isothiocyanates (ITCs), between
themselves and each of them with other bioactives including luteolin (LUT) and curcumin (CUR).
To this aim, a lipopolysaccharide (LPS)-induced RAW 264.7 macrophages model was used to
mimic inflammation. After LPS binds to its receptor (toll-like receptor 4), there is an activation of
common signaling pathway that activate of NF-B, and the upstream kinase cascades (97, 98).
Therefore, cellular NO, and the levels of several inflammation-related proteins were measured
and compared under different treatments. The strength of synergy between combined
treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR were evaluated by the combination index
(CI) value.

4.2 Materials and Methods
4.2.1 Cells Culture and Treatments
Raw 264.7 macrophages were obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were maintained in Roswell Park Memorial Institute (RPMI)-1640
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1
mg/mL streptomycin (Mediatech, Manassas, VA, USA) at 37 C in a humidified atmosphere
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containing 5% CO2. Cells were treated with 2 - 10 µM AIT (98%, Sigma-Aldrich, St. Louis, MO,
USA), 0.25 - 1.25 µM SFN (> 98%, Quality Phytochemicals Edison, NJ, USA), 5 - 25 µM LUT (98%,
Quality Phytochemicals), and 2 - 10 µM CUR (Sigma-Aldrich) as single and combination
treatment with LPS (Sigma-Aldrich, St. Louis, MO, USA) stimulation for 24 hours prior to
detection in each assay. Compounds were dissolved in dimethyl sulfoxide (DMSO) before further
dilution in cell growth medium with a final concentration of 0.1 % v/v DMSO.

4.2.2 Cell Viability and Nitric Oxide Assays
After 24 hours of RAW 264.7 cell seeding in 96-well plates (1.0 × 105 cells/well), cells
were treated with LPS (1 μg/mL) with and without the test compounds followed by the
measurements of cell viability and percentage inhibition of NO production over the following 24
hours (63). To perform NO assay, 150 L of the culture medium was mixed with 100 μL of Griess
reagent (2% sulfanilamide and 0.2% N-(1-naphthyl) ethylenediamine dihydrochloride in
phosphoric acid), the mixture was incubated at room temperature for 30 minutes, and the
absorbance at 540 nm was measured using a microplate reader (SpectraMax, Molecular
Devices, Sunnyvale, CA, USA). Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-Aldrich). Cells in each well were incubated
with 100 L of culture medium containing 0.1 mg/mL MTT at 37 C for 2 hours. MTT containing
medium was removed prior to the solvation of reduced formazan dye using 100 L/well of
DMSO, and the absorbance was measured at 570 nm.

4.2.3 Enzyme-Linked Immunosorbent (ELISA) Assay
After 24 hours of RAW 264.7 cell seeding in 6-well plates (3.75 × 106 cells/well), cells
were treated with LPS (1 μg/mL) with and without the test compounds followed by media
collection over the next 24 hours. Inflammatory cytokines levels which are IL-1β, IL-6, and IL-10
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were analyzed in cytoplasmic cell fraction or in collected medium by ELISA kits according to the
manufacturer’s instruction (R&D Systems, Minneapolis, MN, USA; eBioscience, San Diego, CA,
USA). Absorbance of samples were converted to pg/µg of total protein or pg/mL, respectively.

4.2.4 Western Blotting
After 24 hours of RAW 264.7 cell seeding in 100 mm Petri dishes, cells were treated with
LPS (1 μg/mL) with and without the test compounds. To monitor the expression of p-p65, p65,
and p-IB, cells were collected at 1 hour after treatments. Other proteins expression was
monitored after 24 hours of treatments. To collect cells, cold phosphate buffer saline (PBS) was
used to wash cells that were attaching on the culture plates before detachment using cell
scraper. Nuclear and cytoplasmic fractions were extracted using NE-PER extraction kit (Thermo
Fisher Scientific, Waltham, MA, USA). Whole cell lysate was collected in
radioimmunoprecipitation assay buffer (RIPA buffer) containing protease and phosphatase
inhibitors (Boston BioProducts, Ashland, MA, USA) into Eppendorf tubes and was placed on ice
for 20 minutes. Cell suspensions were then sonicated and were lysed on ice for a further 20
minutes. Supernatants were collected after centrifugation at 20,817 x g for 10 minutes and were
used to determine protein concentrations by bicinchoninic acid (BCA) protein assay. Equal
amounts of proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes (GVS Filter Technology, Indianapolis, IN, USA). Blocking buffer in
PBS was used to block non-specific binding of antibodies prior to immunodetection using
specific antibodies at the manufacturer’s recommended concentrations. Protein bands were
visualized using Odyssey system (LI-COR, Lincoln, NE, USA) after incubation with appropriate
secondary antibodies. Antibodies for p65, p-p65, p-IB, STAT3, and p-STAT3 were purchased
from Cell Signaling Technology (Danvers, MA). Antibodies for iNOS, COX-2, Nrf2, and HO-1 were
from Santa Cruz Biotechnology (Dallas, TX, USA). β-Actin antibody (Sigma-Aldrich) and PARP
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antibody (Cell Signaling) were used as loading controls for whole cell lysate, cytoplasmic
fraction, and nuclear fraction, respectively.

4.2.5 Analyses of Synergy
Synergistic effects of different combinations were analyzed based on Chou and Talalay’s
method (3) with modifications as previously described (63, 67), using R software. This model is
used for a constant ratio of compounds combination. When the combination dose of d1 and d2
provides the same effect x as Drug1 alone at dose Dx,1 and Drug2 alone at dose Dx,2, the
combination index (equation 1) indicates synergism, additivity, or antagonism of the
combinatorial effect when the index <1, =1, or >1, respectively.

Combination index = d1/Dx,1 + d2/Dx,2

(1)

4.2.6 Statistical Analysis
All data were presented as mean + SD. The values were compared to the control using
one-way analysis of variance (ANOVA). The criterion for statistical significance was set at P <
0.05.

4.3 Results
4.3.1 Non-Cytotoxic Effect of Phytochemicals AIT, SFN, LUT, CUR and Their Combinations in
LPS-Induced RAW 264.7 Cells
Cell viability assay was performed in RAW 264.7 cells to ensure non-cytotoxicity of
bioactive compounds used in this study. As shown in Figure 4.1, AIT (2-10 µM), SFN (0.25-1.25
µM), LUT (5-25 µM), CUR (2-10 µM) and their half dose combinations provided more than 90%
cell survival compared to LPS control, suggesting non-cytotoxic effect of the treatments.
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4.3.2 Synergistic Inhibition of LPS-Induced NO Production by the Combination of AIT-SFN,
SFN-LUT, AIT-LUT, and AIT-CUR in RAW 264.7 Cells
During LPS stimulation, macrophages released NO, which was an inflammatory
biomarker used to examine the efficacy of treatments. As shown in figure 4.2A - 4.2D (left
panel), dose- dependent efficacies of single and combination treatments were observed. AIT (2 10 µM), SFN (0.25 - 1.25 µM), LUT (5 - 25 µM) and CUR (2-10 µM) at the indicated
concentrations demonstrated the average ranges of 14.6 - 47.5%, 13.2 - 49.1%, 8.6 - 49.1% and
3.4 - 23.9% NO inhibition, respectively. In terms of reduced dose utilization, the combinatorial
effect between AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1), and AIT-CUR (1:1) at their half
dose serial concentrations provided 20.9 - 53.7%, 11.5 - 55.7%, 17.1 - 67.2%, and 13.0 - 46.2%
NO inhibition, respectively, all of which had higher efficacy compared to their single treatments.
To confirm the enhanced effect from using two bioactives in combination, we further
determined the mode of interaction between each two compounds by using isobologram
analysis based on Chou and Talalay’s method (3). In figure 4.2A - 4.2D (right panel), AIT-SFN
(8:1), LUT-SFN (20:1), LUT-AIT (2.5:1), and AIT-CUR (1:1) showed a synergy with CI less than 1,
especially the pair of AIT and SFN that could provide the lowest CI of 0.50.

4.3.3 Inhibitory Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on LPS-Induced ProInflammatory Cytokines Production
IL-6 and IL-1 are cytokines with potent pro-inflammatory properties. To prove that our
treatments work through these cytokines, ELISA assay was performed. As shown in figure 4.3A 4.3D, LPS significantly increased the level of IL-6 released into cell growth medium to 1,461.1 ±
31.5 pg/mL. Single treatment of AIT (4, and 8 µM), and CUR (4, and 8 µM) did not decreased IL6, while other treatments decreased IL-6 in dose-dependent manner. CI of the combined
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Figure 4.2 Percent inhibition of NO production (Left) and combination indexes (Right) from the
combination treatments of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) in LPSinduced RAW 264.7 macrophages. After 24-hour treatments, NO assay was performed on the
medium. Results are presented as mean ± SD from six replicates.
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treatments were less than 1, demonstrating synergism between each two compounds at
indicated doses. Due to a very low concentration of IL-1β found in the cell growth medium, the
level of this cytokine was determined in the cytoplasmic fraction according to a report of Eder C.
referring to an active form of IL-1β in cytoplasm before being released to extracellular space
(99).

Figure 4.3 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on
the level of IL-6 in cell growth medium after 24-hour treatment in LPS-induced RAW 264.7
macrophages. IL-6 was determined using ELISA. Combination index (CI) ± SE are present in
parentheses. Results are presented as mean ± SD from triplicates (*P < 0.05).
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Like IL-6, LPS significantly increased IL-1β to 151.4 ± 17.0 pg/µg protein (Figure 4.4A - 4.4D).
Single treatments of SFN (0.25, 0.5,1.0 M), LUT (5, 10, 20 M), and CUR (2, 4 ,8 M) dosedependently decreased the level of IL-1 induced by LPS. Unlike other bioactives, AIT at the
concentrations of 4, and 8 M had similar efficacies by lowering IL-1β to 111.6 ± 6.4, 115.4 ± 2.3
pg/µg protein, respectively. However, not all combined bioactives provided a synergy in

Figure 4.4 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on
the level of cytoplasmic IL-1β after 24-hour treatment in LPS-induced RAW 264.7 macrophages.
IL-1β was determined using ELISA. Combination index (CI) ± SE are present in parentheses.
Results are presented as mean ± SD from triplicates (*P < 0.05).
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decreasing IL-1β. Only some concentrations of SFN-LUT, and AIT-LUT provided synergies with
less than 1 of CI value, while AIT-SFN, and AIT-CUR combined treatments were antagonisms with
CI values higher than 1.

4.3.4 Combination Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on an AntiInflammatory Cytokine Production Induced by LPS
To evaluate the potential anti-inflammatory effect of AIT, SFN, LUT, CUR and their
combinations, the level of IL-10 cytokine was determined in the medium. LPS induced IL-10
production to 146.7 ± 5.7 pg/mL (Figure 4.5A - 4.5D). Single treatments of SFN (0.25, 0.5, 1.0
M), and CUR (2, 4 ,8 M) decreased the level of IL-10 in a dose dependent manner with the
highest efficacy of IL-10 reduction to 9.1 ± 7.2, and 61.5 ± 8.2 pg/mL, respectively. However, the
dose-dependent effect was not the case for AIT (2, 4, 8 µM), and LUT (5, 10, 20 M), which their
concentrations of 8 µM AIT and 5 µM LUT most effectively decreased IL-10 to 70.4 ± 5.0, and
106.3 ± 2.5 pg/mL, respectively. For combination treatments, AIT-SFN was the only pair that
lower IL-10 in a dose dependent manner to the lowest level of 14.8 ± 25.6 pg/mL. SFN-LUT
together provided similar efficacy (53.6 ± 21.8 pg/mL IL-10) over the three concentrations. In
addition, the combination of AIT-LUT and AIT-CUR, which did not provide the dose-dependent
effects, most effectively decreased IL-10 to 55.5 ± 26.6, and 11.2 ± 6.7 pg/mL, respectively. The
combination of AIT-SFN (2 µM AIT + 0.25 µM SFN) and AIT-CUR (all three combined
concentrations) provided a synergistic inhibition of IL-10 production while the combination
between SFN-LUT, and AIT-LUT provided an antagonism.
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Figure 4.5 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on
the level of IL-10 in cell growth medium after 24-hour treatment in LPS-induced RAW 264.7
macrophages. IL-6 was determined using ELISA. Combination index (CI) ± SE are present in
parentheses. Results are presented as mean ± SD from triplicates (*P < 0.05).
4.3.5 Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on Protein Expression Under LPSStimulated Condition
Since the AIT - SFN, LUT-SFN, LUT-AIT and AIT-CUR co-treatment excreted potent synergistic
inhibitory effects on multiple pro-inflammatory biomarkers, to better understand their
bioactivities, we investigated the molecular mechanism whether it underlies through NF-B
pathway which is essential for inflammatory control. Expression of a subunit of NF-B, both
phosphorylated (p-p65), and non-phosphorylated (p65) forms, p- IB as well as downstream
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proteins under NF-B regulation which are iNOS, COX-2, and HO-1 was therefore monitored by
Western blotting to observe any correspondence with the level of NO being released from the
cells. The results in Figure 4.6 - 4.9A demonstrated that single and combination treatment of
AIT, SFN, LUT and CUR could decrease the expression level of p-p65 and p65 in the nucleus after
1 hour of LPS stimulation, especially the combination treatments (AIT-SFN, LUT-SFN, LUT-AIT
and AIT-CUR) that decreased the expression of nuclear p-p65 as much as 42%, 42%, 19%, and
39%, respectively. Nuclear p65 was also decreased by AIT-SFN, LUT-SFN, and LUT-AIT as much as
33%, 39%, and 44%, respectively while it was not decreased by AIT-CUR. Correspondingly, the
expression of LPS-stimulated p-IB, which occurs when freeing NF-B from the inhibitory
complex (NF-B - IB binding) in cell cytoplasm was decreased by treatments, especially when
they were combined. AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR enhanced p-IB expression after 1
hour of LPS stimulation in comparison to the effect from each bioactive. This effect was even
more obvious at hour-24 after LPS stimulation. The combination of AIT-SFN, LUT-SFN, LUT-AIT
and AIT-CUR could inhibit p-IB as high as 85%, 92%, 64%, and 82%, respectively in whole cell
lysates (Figure 4.6 - 4.9B).
Expression of proteins under regulation of the transcription factor NF-B was
monitored. Pro-inflammatory proteins (iNOS and COX-2) in cell lysates were decreased by
treatments. The combination of AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR dose-dependently
enhanced the reduction of iNOS expression compared to a single treatment by lowering the
protein expression to 22%, 6%, 18%, and 15%, respectively. The expression of COX-2 was not as
sensitive to these treatments as iNOS. The highest concentrations of the combined treatments
of AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR only decreased COX-2 expression to 63%, 80%, 63%,
and 81%, respectively, which this effect was not always dose-dependent.

76

Figure 4.6 Representative Western blots demonstrating combination effects of AIT and SFN in
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates
were monitored after 24-hour treatments. The protein band intensities underneath the blots
were quantified using Image Studio software. PARP and β-Actin served as internal controls for
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are
representative of at least 3 experiments.
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Figure 4.7 Representative Western blots demonstrating combination effects of SFN and LUT in
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates
were monitored after 24-hour treatments. The protein band intensities underneath the blots
were quantified using Image Studio software. PARP and β-Actin served as internal controls for
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are
representative of at least 3 experiments.
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Figure 4.8 Representative Western blots demonstrating combination effects of AIT and LUT in
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates
were monitored after 24-hour treatments. The protein band intensities underneath the blots
were quantified using Image Studio software. PARP and β-Actin served as internal controls for
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are
representative of at least 3 experiments.
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Figure 4.9 Representative Western blots demonstrating combination effects of AIT and CUR in
LPS-induced RAW 264.7 cells on the expression of p65 subunit of NF-B in both phosphorylated
and non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an
hour of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell
lysates were monitored after 24-hour treatments. The protein band intensities underneath the
blots were quantified using Image Studio software. PARP and β-Actin served as internal controls
for nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are
representative of at least 3 experiments.
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Regarding considerable evidence suggesting links between oxidative stress and
inflammation, the expression of HO-1, which is an antioxidant protein known to possess antiinflammatory function (11, 27, 100), was monitored in cell lysates through Western blotting. We
found that both single and combined treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR
increased HO-1 expression in a dose-dependent manner. The enhanced effect was observed
from using combined treatments. AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR maximally increased
HO-1 expression to 246%, 223%, 568%, and 223%, respectively compared to LPS positive
control.

4.4 Discussion
Utilizing combined bioactives to treat diseases has recently received a significant
amount of attention due to possibilities of increasing therapeutic efficacies while reducing
doses. Major advantages of this strategy are to avoid the risk of overdose toxicity and to reduce
the development of treatment resistance (3). In this study, we aimed to evaluate the potential
synergistic anti-inflammatory activities of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR in
combinations, as well as to investigate their molecular mechanisms in LPS-induced RAW 264.7
macrophages.
Cell viability under single and combinatorial treatments were firstly obtained to ensure
non-cytotoxicity of treatments that were used throughout this study. LPS significantly increased
NO in cell growth medium but treatments provided at the same time as LPS could significantly
inhibit NO production in a dose-dependent manner. As a single treatment, SFN (0.25 - 1.25 µM)
demonstrated higher efficacy than AIT (2 - 10 µM) > CUR (2 - 10 µM) > LUT (5 - 25 µM)
respecting their efficacies and ranges of dose utilization. Nevertheless, when two of them were
combined based on their efficacies as AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1) and AIT-CUR
(1:1), the synergy in the inhibition of NO production was observed, suggesting the possibility of

81

lowering doses of each compound which would avoid toxicity risk from too high concentrations
that might bring about metabolic problem (101). Each pair of the combined treatments had
different trends of CI values over dose ranges, which this effect could be specific to types of
compounds and ratio of the combination. The combined treatment of AIT-SFN, and AIT-CUR had
higher CIs when their doses were increased, suggesting a reduction of degree of synergism with
the increment of concentrations. As the concentration of AIT-LUT combination increased, the CI
values decreased and became constant, suggesting an increased degree of synergism until a
certain concentration before reaching constant. CI values of SFN-LUT combination tended to be
constant over the dose range, suggesting similar degrees of synergism.
Besides NO, inflammatory cytokines were determined. The reduction of LPS-induced
pro-inflammatory cytokines, IL-6, and IL-1β, by AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR
combination were significant and dose-dependent. Synergisms were found from all four
combined treatments in the inhibition of IL-6 production. Unlike IL-6, not all the combined
treatments synergistically inhibited IL-1β production. The combination between AIT-SFN, and
AIT-CUR provided an antagonistic effect on the inhibition of this pro-inflammatory cytokine
production. Only SFN-LUT, and AIT-LUT combined treatments could provide synergistic decrease
of IL-1β production. In addition, among four compounds (AIT, SFN, LUT, and CUR) under dose
ranges that provide similar efficacy on the inhibition of NO production, LUT more obviously
inhibited IL-1β production compared to other compounds. This information suggests that LUT
had different anti-inflammatory properties in comparison to AIT, SFN, and CUR. Therefore, using
LUT to combine with either AIT or SFN could provide a synergism because they enhanced each
other’s effects potentially through different mechanisms. Besides, the trends of CI values of
both IL-6, and IL-1β pro-inflammatory cytokines over a dose range were different from that of
NO inhibition, suggesting partial involvement of these cytokines in NO production. A study in
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human macrophage demonstrated that not only IL-6, but also IL-10, which is an antiinflammatory cytokine, could regulate activation of a transcription factor STAT3 that as a
consequence was able to regulate expression of iNOS, an enzyme catalyzing NO production (30,
102).
In addition to the levels of pro-inflammatory cytokines, we determined the level of an
anti-inflammatory cytokine, IL-10. Only the combination of 2 µM AIT with 10 µM LUT
significantly increased IL-10 production. The rest of the treatments, most of them including the
combined treatments significantly decreased LPS-induced IL-10 production but not in a dosedependent fashion. However, CIs indicated a synergism only at low concentrations of AIT-SFN
combined treatment, and all concentrations of AIT-CUR combined treatments. The combination
between SFN-LUT and AIT-LUT provided antagonistic effect in the decrease of IL-10 production.
Although IL-10 has been known to provide anti-inflammatory effects by preventing damage and
maintaining normal tissue homeostasis, it is not clear whether an elevation of this cytokine
during infection is a cause or a consequence of high pathogen burden (103). Different levels of
IL-10 had been produced by compounds and herbal extracts possessing anti-inflammatory
properties. In LPS-stimulated macrophages some of which, including DG1102 herbal mixture
(104), N-trans-ϱ-caffeoyl tyramine (105), and the mixtures of recombinant growth factors (106),
decreased the expression level of IL-10 while the others such as metformin (107), and glyceollins
(108), increased the level of this inflammatory cytokine. In addition, an anti-inflammatory study
of dantrolene in LPS-induced RAW 264.7 cells and in LPS-challenged mice exhibited different
effects on the level of IL-10 (109). Dantrolene, which decreased a pro-inflammatory cytokine
TNF-α in both in vivo and in vitro, increased IL-10 in the animal plasma but decreased the IL-10
released by RAW 264.7 cells. These data suggest differential regulation of IL-10 by different
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compounds under inflammatory events in vitro and in vivo. Thus, further study is necessary for a
better understanding in the regulations and roles of this inflammatory cytokine.
To further clarify molecular mechanisms of the inhibitory effects of the combined
treatments on inflammatory mediators, we investigated the effects of the treatment on the
activation of a transcription factor, NF-B (p-p5, and p65), and its related proteins in LPSstimulated macrophages. Our Western blot results showed that AIT, SFN, LUT, and CUR inhibited
LPS-induced expression of p-p65, p65, and p-IB which is a feedback control of NF-B activation.
This observation corresponded with previous studies reporting that AIT, SFN ,LUT and CUR
alone inhibits NO production through the NF- B pathway (57, 63, 66, 110). The combined
treatments of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR enhanced the inhibition of nuclear p-p65,
and p65, as well as the inhibition of cytosolic p-IB expression after one hour of LPS stimulation
and bioactive compounds treatment. The enhanced effects from using these combined
treatments were more obvious in the expression of p-IB after 24 hours of LPS stimulation and
bioactives application. Similar enhanced effects were observed in protein expression of iNOS
and COX-2, which are known to be regulated through this pathway (23). The trends of p-p65,
p65, and p-IB expression were similar to those of iNOS, COX-2, as well as the level of IL-6, and
IL-1β, confirming the regulatory effects of treatments on the mentioned pro-inflammatory
proteins through NF-B. Although IL-10 has also been recognized under NF-B regulation, no
corresponding trend was observed in this study, suggesting other transcription factors playing a
role over NF-B. Saraiva M., and O’Garra A. reported more than one transcription factor (such
as NF-B, CREB, and MAF) that control IL-10 expression in macrophage (111).
In terms of percent reduction of protein expression, iNOS was more sensitive to our
combined treatments than COX-2, suggesting higher efficacy of the treatments to decrease the
production of NO over prostaglandins (PGs). This information introduced the idea using a COX-2
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inhibitor to combine with our treatments for improving anti-inflammatory properties of
phytochemicals, thus more studies are necessary.
Studies have shown a sustained relationship between oxidative stress and inflammation.
ROS can activate the NF-B pathway responding to many cellular activities including
inflammation (11). Therefore, HO-1, which is an important phase-2 antioxidant protein was
examined. The results showed that AIT, SFN, LUT, and CUR dose-dependently increased HO-1
expression. Moreover, their combination between AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR
enhanced the induction of this protein expression.
In conclusion, combinatorial treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR
provided synergistic anti-inflammatory effects by reducing NO production in LPS-induced RAW
264.7 macrophages. Mechanistic action of this consequence was possibly achieved at least
partially through the NF-B pathway and cellular antioxidative system as the expressional level
of p65, p-p65, p-IB, iNOS, COX-2, IL-6, and IL-1 were decreased with an induction of the
antioxidant proteins HO-1. This information provides an alternative notion of bioactive
compounds in combinations for inflammation treatment.
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CHAPTER 5
SYNERGISTIC ANTIOXIDANT EFFECTS OF ALLYL ISOTHIOCYANATE AND SULFORAPHANE ON
TERT-BUTYL HYDROPEROXIDE-INDUCED RAW 264.7 CELLS

5.1 Introduction
An overproduction of reactive oxygen species (ROS) causes oxidative stress, in turn
damaging biological molecules such as lipids, proteins, and DNA, and being implicated in many
pathological conditions including cardiovascular disease, neurological disorders, diabetes, and
cancer (11, 12, 19). Under high ROS conditions, the transcription factor Nrf2, a key regulator of
phase 2 antioxidant and detoxification enzymes, is activated. In cytoplasm, ROS modify protein
structure of Keap-1 which is a repressor of Nrf2, leading to a dissociation between Keap-1 - Nrf2.
After that, free Nrf2 is phosphorylated and translocated into the nucleus to bind to antioxidant
responsive elements, allowing an increased expression of cellular antioxidant proteins (36).
Similar to Nrf2, the transcription factor NF-B, a key regulator of inflammatory process,
immunity, cell proliferation and apoptosis, is also activated by ROS (11). NF-B dissociates from
IB after both of them are phosphorylated. Free phosphorylated NF-B translocates into the
nucleus and upregulates expression of numerous target genes that control apoptosis (112).
To increase cellular antioxidant capacity for counteracting oxidative damages,
antioxidants, especially from natural resources, have received attention and have been
considered as therapeutic agents. Allyl isothiocyanate (AIT), and sulforaphane (SFN), which are
dietary isothiocyanates (ITCs) derived from glucosinolates in cruciferous vegetables, have
demonstrated antioxidant activities through the activation of Nrf2-Antioxidant Response
Element (ARE) Signaling Pathway. ITCs react with specific thiol groups on Keap-1 and form
thionacyl adducts, which promotes dissociation of Nrf2 from Keap-1, and allows subsequent
activation of ARE-driven genes including phase 2 antioxidant and detoxification proteins (46).
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They also have been shown to decrease ROS during inflammation through both Nrf2 and NF-B
transcription factors (110, 113). Cell culture studies show that ITCs significantly enhanced mRNA
and protein expression of phase 2 enzymes heme oxygenase-1 (HO-1) and NAD(P)H: quinone
oxidoreductase-1 (NQO-1) (83, 114). HO-1 is a part of natural defense mechanisms, which is
important in preservation of tissue integrity against oxidative stress. By-products of HO-1
catabolism including carbon monoxide (CO), biliverdin, and bilirubin, have protective effects. CO
contributes to the attenuation of inflammation while bilirubin is a potent peroxyl radicals
scavenger (27). NQO-1 demonstrates its antioxidant through reductase activity by converting
quinone to dihydroquinone. This enzymatic reaction prevents one electron reduction of
quinones forming semiquinone, a free radical, that can be induced by ROS (115). In an animal
experiment, ITCs increased tissue levels as well as the activities of quinone reductase, and
glutathione-S-transferase (GST) (83, 116). Glutathione (GSH) plays a role as a reducing agent to
maintain thiol groups on intracellular proteins and antioxidant molecules (92). GST catalyzes the
conjugation of GSH via a sulfhydryl group to electrophilic centers of variety of substrates and
makes the compounds more water-soluble. This activity detoxifies endogenous compounds such
as lipid peroxides and enables the breakdown of xenobiotics (117).
However, the antioxidant study of ITCs in combination, particularly AIT and SFN, and
their mechanisms of action have not been well defined. The present study compared viability of
RAW 264.7 cells, which the single or combined ITCs treatment was given before being
challenged in tert-butyl hydroperoxide (t-BHP), a known ROS producer. The metabolism of t-BHP
in vivo produces alkyl- and peroxyl radicals, that can initiate lipid peroxidation, deplete
intracellular GSH, and decrease antioxidant enzymes activities, all of which result in biological
damages and cell death (118, 119). Thus, using the t-BHP-induced oxidative damage model
allowed us to evaluate the antioxidant potential of AIT-SFN combined treatments, and
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compared underlying molecular mechanisms of the combined ITCs with each individual
compound. We assessed not only cell viability, but also cellular ROS, GSH, GST activity, as well as
the expression of key transcription factors (Nrf2 and NF-B), and phase 2 antioxidant proteins.

5.2 Materials and Methods
5.2.1 Cell Culture and Treatments
Raw 264.7 macrophages were obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were maintained in Roswell Park Memorial Institute (RPMI)-1640
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1
mg/mL streptomycin (Mediatech, Manassas, VA, USA) at 37 C in a humidified atmosphere
containing 5% CO2. To investigate the question of whether AIT and SFN in combination can
attenuate oxidative damage, cells were treated with 0.25 - 1.25 µM AIT (98%, Sigma-Aldrich, St.
Louis, MO, USA), 0.01 - 0.05 µM SFN (> 98%, Quality Phytochemicals Edison, NJ, USA), and their
combinations for 24 hours with or without t-BHP (Sigma-Aldrich, St. Louis, MO, USA)
challenging. Compounds were dissolved in dimethyl sulfoxide (DMSO) before further dilution in
cell growth medium with a final concentration of 0.1 % v/v DMSO.

5.2.2 Cell Viability Determination
Raw 264.7 macrophages were pre-treated with AIT, SFN, and their combinations for 24
hours with or without prior t-BHP challenging at 1000 µM for 3 hours, before subjecting to cell
viability test. Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT; Sigma-Aldrich). Cells in each well were incubated with 100 µL of
culture medium containing 0.5 mg/mL MTT at 37 C for 1 hours. MTT containing medium were
removed prior to the solvation of reduced formazan dye using 100 µL/well of DMSO, and the
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absorbance was measured at 570 nm using a microplate reader (SpectraMax, Molecular
Devices, Sunnyvale, CA, USA).

5.2.3 ROS Measurement
ROS measurement is performed in RAW 264.7 cells after t-BHP challenging using
dichlorofluorescein-diacetate (DCFH-DA) assay. After the removal of cell culture medium, cells
were incubated with 5 µM DCFH-DA in serum-free RPMI medium without phenol red for 30
minutes in the dark at 37 C. Excess DCFH-DA that didn’t penetrate into the cells was washed off
with the medium. Cellular esterase can cleave the ester bond in DCFH-DA yielding DCFH, which
would be oxidized by ROS and would then become a fluorescent compound, DCF. Fluorescence
detection at the excitation and emission wavelengths of 485/528 nm was monitored using a
multi-detection reader (Synergy HT, Biotek Instruments Winooski, VT, USA) after 100 μL addition
of the medium. Cellular ROS level were relatively determined in comparison to the control and
the data were normalized by cell viability.

5.2.4 Determination of GSH Level
Cell lysates were prepared in 100 mM potassium phosphate buffer, pH 7.0, containing 2
mM EDTA, followed by deproteination of samples using metaphosphoric acid (10% w/v,
aqueous solution), and triethanolamine. GSH level was determined using a colorimetric assay kit
(Cayman Chemical, Ann Arbor, MI, USA) according to the manufacture’s instruction. Lysate
samples were mixed with DTNB (5,5'-dithiobis-2-nitrobenzoic acid, Ellman’s reagent) along with
other assay cocktail containing cofactor, enzyme mixture, MES buffer, and water. DTNB can
form a conjugation with GSH in the sample and become GSTNB, which is then reduced by
glutathione reductase in the cocktail to TNB and reformed GSH. TNB which its level is
proportional to that of GSH is detectable with absorbance measurement at 412 nm. GSH
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concentration was calculated based on a standard curve and it was normalized by protein
concentration.

5.2.5 Determination of GST Enzyme Activity
Cell lysates were prepared in 100 mM potassium phosphate buffer, pH 7.0, containing 2
mM EDTA. GST activity was determined using a colorimetric assay kit (Cayman Chemical)
according to the manufacture’s instruction. Based on the function of GST that conjugate
toxicants with GSH, CDNB (1-chloro- 2,4-dinitrobenzene) and GSH were added to cell lysates,
allowing GST in the sample to catalyze conjugation between CDNB and GSH. Kinetic absorbance
of the conjugation was measured at 340 nm. The rate of absorbance increase was directly
proportional to the GST activity in the sample, which was finally normalized by protein
concentration.

5.2.6 Western Blotting
After 24 hours of RAW 264.7 cell seeding in 100 mm Petri dishes, cells were treated with
ITCs with or without t-BHP challenging. Cell lysates, nuclear fraction, and cytoplasmic fraction
were collected and used in Western blotting. To collect cells, cold phosphate buffer saline (PBS)
was used to wash cells that were attaching on the culture plates before detachment using cell
scraper. Nuclear and cytoplasmic fractions were extracted using NE-PER extraction kit (Thermo
Fisher Scientific, Waltham, MA, USA). The whole cell lysate was collected in
radioimmunoprecipitation assay buffer (RIPA buffer) containing protease and phosphatase
inhibitors (Boston BioProducts, Ashland, MA, USA) into Eppendorf tubes and was placed on ice
for 20 minutes. Cell suspensions were then sonicated and were lysed on ice for a further 20
minutes. Supernatants were collected after centrifugation at 20,817 x g for 10 minutes and were
used to determine protein concentrations by bicinchoninic acid (BCA) protein assay. Equal
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amounts of proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes (GVS Filter Technology, Indianapolis, IN, USA). Blocking buffer in
PBS was used to block non-specific binding of antibodies prior to immunodetection using
specific antibodies at the manufacturer’s recommended concentrations. Protein bands were
visualized using Odyssey system (LI-COR, Lincoln, NE, USA) after incubation with appropriate
secondary antibodies. Antibodies for Nrf2, HO-1, NQO-1 were from Santa Cruz Biotechnology
(Dallas, TX, USA). Antibodies for p65, and p-p65, which are subunits of NF-B, were purchased
from Cell Signaling Technology (Danvers, MA). β-Actin antibody (Sigma-Aldrich) and PARP
antibody (Cell Signaling) were used as loading controls.

5.2.7 Analyses of Synergy
Synergistic effects of different combinations were analyzed based on Chou and Talalay’s
method (3) with modifications (63, 67) using R software. This model is used for a constant ratio
of compounds combination. When the combination dose of d1 and d2 provides the same effect x
as Drug1 alone at dose Dx,1 and Drug2 alone at dose Dx,2, the combination index (CI; equation 1)
indicates synergism, additivity, or antagonism of the combinatorial effect when the index <1, =1,
or >1, respectively.

Combination index = d1/Dx,1 + d2/Dx,2

(1)

5.2.8 Statistical Analysis
All data were presented as mean + SD. The values were compared to the control using
one-way analysis of variance (ANOVA). The criterion for statistical significance was set at P <
0.05.
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5.3 Results
5.3.1 Combination of AIT and SFN Synergistically Attenuated t-BHP-Induced Cytotoxicity in
RAW 264.7 Cells
As shown in figure 5.1A, 1000 µM t-BHP challenging for 3 hours significantly decreased
RAW 264.7 cell viability from 100% to 17.3 ± 2.4%. On the other hand, ITCs, both as a single and
combined treatment, significantly reduced t-BHP-induced cytotoxic effects in dose-dependent
manner. Concentrations of ITCs used in this experiment were based on the potencies of each
single compound that provided less than 50% protective effect, sparing some space for the
combination to show off their efficacies. Single treatments of AIT (0.25 - 1.25 µM), and SFN (0.01
- 0.05 µM) increased cell viability to a range of 17.4 - 42.7%, and 18.2 - 41.8%, respectively,
while their half-dose combination provided an enhanced effect by increasing number of viable
cells to a range of 16.4 - 52.4% with a synergy. The CIs of AIT-SFN combined treatment
calculated based on Chou and Talalay’s method (3), were in a range of 0.50 - 0.74.
To ensure non-cytotoxicity of the treatments under normal condition, viability of RAW
264.7 cells treated with the single or combined ITCs was determined. The results showed that
without t-BHP, none of the treatments significantly changed viability of RAW 264.7 cells (98.8 107.4%) compared to DMSO control (Figure 5.1B).

5.3.2 AIT and SFN Provided Synergistic Reduction of Cellular ROS Induced by t-BHP
To further investigate the protective effects of ITCs, the level of intracellular ROS was
determined. As illustrated in figure 5.2, t-BHP increased 90.3% ROS level in the cells. However,
treatment exposure prior to t-BHP challenge attenuated cellular ROS. Single treatment of AIT
(0.25-1.25μM) or SFN (0.01-0.05 μM) significantly diminished t-BHP-induced ROS in RAW 264.7
cells by 23.5 - 62.8%, and 22.9 - 61.4%, respectively, while their half-dose combination
synergistically decreased ROS by 38.8 - 71.6% with a range of CI from 0.50 - 0.86.
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Figure 5.1 Viability of RAW 264.7 cells under single and combination treatments of AIT and
SFN with (A) and without (B) t-BHP challenge. Cells were treated with series of treatment
concentrations for 24 hours before being exposed to 1000 µM t-BHP for 3 hours. Viability
measurement was performed using MTT assay. Combination index (CI) ± SE are present in
parentheses. The data represent the mean ± SD from at least four replicates.

5.3.3 Different Effects of AIT and SFN in Combination Compared between Conditions with and
without t-BHP Challenge on Cellular GSH Level
Based on the properties of ITCs that could decrease intracellular ROS induced by t-BHP,
we continue studying their antioxidant effects by assessing GSH level in the cells under
conditions with or without oxidative stress. AIT, and SFN concentrations that significantly
decreased ROS level in the previous experiment were selected for GSH determination.
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Figure 5.2 AIT, SFN and their combination scavenged t-BHP-induced ROS generation in RAW
264.7 cells. Intracellular ROS was relatively determined by DCFH-DA assay after 24-hour
treatments and/or 3-hour t-BHP exposure. Results are presented as mean + SD from four
replicates. Combination index (CI) ± SE are present in parentheses. (*P < 0.05 vs. untreated
group)

Figure 5.3 shows that under normal condition, single treatment of both AIT (1 µM) and SFN
(0.04 µM) did not significantly change cellular GSH level, while their combination treatments
(0.5 µM AIT + 0.02 µM SFN, and 1 µM AIT + 0.04 µM SFN) significantly decreased GSH level in
the cells by 9.3, and 19.8%, respectively. Under oxidative stress condition, t-BHP decreased GSH
level by 37.7%. However, all treatments significantly increased cellular GSH diminished by t-BHP.
AIT (1 µM) and SFN (0.04 µM), increased GSH level by 27.8, 14.4%, respectively compared to tBHP treated control. Their combination (0.5 µM AIT + 0.02 µM SFN, and 1 µM AIT + 0.04 µM
SFN) dose-dependently increased GSH by 9.8, and 22.8%, respectively.
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Figure 5.3 Effects of AIT, SFN and their combination on GSH concentration in RAW 264.7 cells.
Cells were 24-hour treated with different compounds with or without 3-hour t-BHP exposure.
Total GSH level was determined by Ellman’s reagent. The data represent the mean ± SD from
triplicates (*P < 0.05 vs. untreated group, #P < 0.05 vs. t-BHP treated group).

5.3.4 Different Effects of AIT and SFN in Combination Compared between Conditions with and
without t-BHP Challenge on Cellular GST Activity
GST is a phase 2 enzyme, best known for its ability to catalyze conjugation of reduced
GSH to xenobiotic substrates for the purpose of detoxification. Regarding the ITCs effect on GSH,
we also determined the effect of AIT, SFN and their combination on GST activity, under both
normal and t-BHP stress conditions. As shown in Figure 5.4, under normal condition, only 1 µM
AIT significantly increased 20.3% GST activity in comparison to the DMSO control. SFN and the
combination treatments did not significantly change cellular GST activity. Similar to the GSH
level, t-BHP decreased 16.3% GST activity from the control. However, under oxidative stress
condition, 1 µM AIT and high concentration of the combined treatment (1 µM AIT + 0.04 µM
SFN) significantly increased GST activity by 46.7, and 35.0%, respectively. SFN (0.04 µM) and the
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lower concentration of the combined treatment did not alter cellular GST activity diminished by
t-BHP.

Figure 5.4 Effects of AIT, SFN and their combination on GST activity in RAW 264.7 cells.
Cells were 24-hour treated with different compounds with or without 3-hour t-BHP exposure.
GST activity was determined by CDNB assay. The data represent the mean ± SD from triplicates
(*P < 0.05 vs. untreated group, #P < 0.05 vs. t-BHP treated group).

5.3.5 Effects of AIT, SFN, and Their Combination on Protein Expression
Protective properties of antioxidants in cells are commonly related to their ability to
induce cytoprotective enzymes, which includes phase 2 detoxification proteins such as GSH,
GST, Nrf2, HO-1, and NQO-1. In this respect, we investigated whether AIT, SFN and their
combination treatments affected the expression of Nrf2 in the nucleus, as well as the expression
of HO-1, and NQO-1 in the whole cell lysate. The nuclear expression of Nrf2 transcription factor,
which is a regulator of the anti-oxidant response, was decreased by all ITCs treatment, especially
by the AIT-SFN combination (Figure 5.5A). Low ITCs concentrations used in this study did not
change much of HO-1, and NQO-1 expression (Figure 5.5B). The combination of AIT and SFN
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enhanced a decrement of HO-1 expression under no stress condition, which is similar to the
cellular GSH level.

Figure 5.5 Representative Western blots demonstrating effects of AIT and SFN in RAW 264.7
cells on the expression of nuclear Nrf2 (A), and the expression of HO-1, and NQO-1 from whole
cell lysates (B) after 24-hour treatments. PARP and β-Actin served as internal controls for
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are
representative of at least 3 experiments.

5.3.6 Effects of AIT, SFN, and Their Combination on Protein Expression under Oxidative Stress
Condition
To further clarify cytoprotective effects of ITCs, protein expression was monitored after
t-BHP challenge in ITCs pre-treated cells. Similar to cellular GSH levels, nuclear expression of
Nrf2 in RAW 264.7 cells was decreased by t-BHP but ITCs pretreatment was able to increase this
protein expression under stress consition, except the highest AIT-SFN combination that
decrease the expression in the nucleus (Figure 5.6A). The expression of HO-1, and NQO-1, which
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Figure 5.6 Representative Western blots demonstrating combination effects of AIT and SFN in
t-BHP-induced RAW 264.7 cells on the expression of p-p65 subunit of NF-B and Nrf2 in the
nucleus (A), the expression of p-p65, and p65 in the cell cytoplasm (B), and the expression of
HO-1, and NQO-1 from whole cell lysates (C) after 24-hour treatments with t-BHP challenge.
PARP and β-Actin served as internal controls for nuclear fraction and cytosolic fraction or whole
cell lysate, respectively. The results are representative of at least 3 experiments.
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are under Nrf2 regulation, was also decreased by t-BHP, but all ITCs pretreatment, especially the
highest concentrations of AIT-SFN combination, obviously increased expression of these
proteins in the cells by 11.5-, and 5.8-fold, respectively (Figure 5.6C).
Besides Nrf2, we also monitored expression level of p65 subunit of NF-B due to its
sensitivity to ROS (120), and its roles in regulating expression of antioxidant proteins as well as
in controlling apoptosis (112, 121). Figure 5.6A and B clearly show that t-BHP increased p-p65
expression in both nucleus and cytoplasm. Most ITCs treatment enhanced p-p65 localization in
the nucleus but not in a dose-dependent manner, except 0.5 µM AIT that slightly decreased pp65 expression in the nucleus. In cell cytoplasm, all ITCs treatments decreased p-p65 with no
dose-response relationship. Similar to p-p65 in cytoplasm, the expression of p65 was increased
by t-BHP. Most treatments also increased this protein expression, except the highest
concentration of AIT-SFN combination that decreased its expression level.

5.4 Discussion
To prevent oxidative stress-induced cells or tissues damage, phytochemicals derived
from our daily diet have received much attention because of their antioxidant properties. ITCs
which are rich in cruciferous vegetables demonstrate antioxidant activities through an induction
of Nrf2 transcription factor. However, the antioxidant study of ITCs in combination, particularly
AIT and SFN, and their mechanistic action underlying antioxidant potential are not sufficiently
understood. Therefore, we evaluated the enhanced effects of AIT-SFN combined treatment on
the inhibition of oxidative stress-induced cell death.
Low concentrations of AIT (0.25 - 1.25 µM), and SFN (0.01 - 0.05 µM), which
demonstrated no toxic effects in RAW 264.7 cells, were used in this study. t-BHP significantly
reduced cell viability but pre-treatment with ITCs decreased the number of cells death. As a
single treatment, SFN demonstrated higher efficacy than AIT according to the lower range of
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dose utilization in RAW 264.7 cells. In fact, the effect of various ITCs varies among cells and
tissues. For example, SFN was more effective than AIT in isolated cells, but they had similar
activity in vivo in terms of phase 2 protective enzymes induction (122). When both of them were
half-dose combined with the ratio of AIT:SFN being 25:1 based on their efficacies, the synergy in
attenuation of t-BHP-induced cells death was observed. The combination of AIT and SFN
provided higher efficacy than each of them being used alone, suggesting the possibility to
increase the therapeutic efficacy by reducing the dosage in order to avoid the risk of overdose
toxicity and to reduce the development of treatment resistance (3).
The synergistic cytoprotective effect from combined AIT-SFN pre-treatment inversely
correlated with relative levels of intracellular ROS. t-BHP caused a sharp increase
of ROS generation, which was synergistically attenuated by the combined treatment. These
results indicated an enhanced antioxidant effects of the combination that protected RAW 264.7
cells from t-BHP. In fact, pre-treatment of ITCs was necessary for RAW 264.7 cells to obtain the
antioxidant effect. Without pre-treatment, ITCs application at the same time as t-BHP challenge
did not recover cell viability (data not shown). This was possibly because ITCs at the
concentrations used in this study did not possess direct antioxidant effect to scavenge free
radicals generated by t-BHP. In addition, our in vitro experiments demonstrated that AIT and
SFN did not have 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 2,2’-azobis(2-amidinopropane)
(AAPH) scavenging activity (data not shown). However, ITCs alone have been shown to possess
indirect antioxidant activity by inducing phase 2 antioxidant and detoxification proteins such as
GSH, GST, HO-1, and NQO-1, through the regulation of Nrf2 transcription factor (83, 114).
Therefore, we examined these proteins level whether they were affected by the combination
treatment of AIT and SFN.
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Recent studies suggested that phytochemicals could directly activate Nrf2 by binding to
Keap1 through covalent linkages, resulting in the induction of cytoprotective proteins, such as
HO-1 (123). We investigated the effects of ITCs and their combination under conditions with and
without oxidative stress.
Under no stress, the nuclear translocation of Nrf2 was decreased by ITCs, which
corresponded with cellular protein expression of HO-1, and GSH level that were significantly
decreased by AIT-SFN combined treatments, while NQO-1 expression was not changed. The low
concentrations of ITCs (0.04 µM SFN and/or 1 µM AIT) used in this study may convey this effect.
Other study demonstrated an increased Nrf2 expression in the nucleus when the minimum
concentration of 5 µM SFN, or 10 µM AIT was applied to NIH3T3 fibroblast (83). The same study
also showed an increase of HO-1, and NQO-1 expression under 5 µM of AIT or SFN treatment.
Another support was found in SH-SY5Y dopaminergic-like neuroblastoma that required at least
2.5 µM of SFN to significantly increased total GSH level (124). However, 1 µM AIT significantly
increased enzyme activity of GST. These data suggested a possibility of co-regulation of
transcription factors under this ITC treatment. Morceau et al.(125) verified that NF-B, which is
sensitive to cellular redox system was involved in GST regulation of K562 leukemia cells. Besides,
post-transcriptional and/or post-translational modification of GST can affect its enzymatic
activity, thus further studies are necessary.
Under t-BHP-induced oxidative stress condition, the nuclear translocation of Nrf2 was
decreased, which was in accordance with the levels of its downstream proteins GSH, HO-1, and
NQO-1, as well as GST enzyme activity. However, pre-treatment of cells with ITCs reversed the
adverse effects of t-BHP, especially AIT-SFN combined treatment that obviously increased HO-1,
and NQO-1 expression in a dose-dependent manner. ITCs pre-treatment might protect cellular
proteins against t-BHP toxicity so they could function under stress condition. However, the
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highest concentration of AIT-SFN combination decreased Nrf2 in the nucleus, suggesting a
presence of more than one transcription factor besides Nrf2 that regulated these phase 2
antioxidant and detoxification proteins under ITCs treatment.
Since NF-B is also involved in cellular redox system, its nuclear and cytoplasmic
expression was monitored under ITCs treatment. As expected, the expression of NF-B (p65
subunit) both phosphorylated and non-phosphorylated forms were increased by the prooxidant, t-BHP, in RAW 264.7 cells as a defense mechanism. ITCs treatment did not clearly
decrease the phosphorylated form (p-p65) in the nucleus but they did clearly decrease p-p65 in
the cytoplasm although not in a dose-dependent pattern, suggesting partial involvement of this
NF-B subunit in the protective effects of ITCs. The expression of non-phosphorylated form
(p65) in the cytoplasm was slightly increased by the treatments except the highest
concentration of AIT-SFN combination that decreased its expression. Studies have shown that
NF-kB regulates not only phase 2 proteins, but also apoptosis as either a pro- and anti-apoptotic
regulator (112, 121), which may explain non-dose-dependent expression level of p-p65, and p65
in the cells under oxidative stress-induced cell death condition.
In conclusion, despite the fact that ITCs, particularly AIT and SFN, exert their protection
against oxidative stress through their indirect antioxidant property, this study shows that these
two ITCs in combination can provide a synergistic cytoprotective potential against oxidative
damage by increasing antioxidant effects, decreasing cellular ROS, and increasing viability of
RAW 264.7 cells. The antioxidant effects of these ITCs including their combination were
obviously completed through phase 2 antioxidant and detoxification proteins including GSH,
GST, HO-1, and NQO-1, some of which had more dominant effects than the others, under partial
regulation of Nrf2, and NF-B transcription factors. This information provides a rationale to
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develop ITCs preparation for prevention of oxidative stress-related diseases and therapeutic
applications.
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CHAPTER 6
CONCLUDING REMAKRS

As cancer research progresses, we have become increasingly aware that oxidative stress
and inflammation have been linked to this multi-stage disease during initiation, promotion, and
progression. The modulation of cellular redox homeostasis holds promise as effective cancer
prevention and treatment with specificity targetting cancer cells, due to differences in reactive
oxygen species (ROS) levels between normal and tumor cells. Blocking a source of inflammation
can enhance cancer immunotherapy (19). This array of events significantly increases the
likelihood to develop combinatorial anticancer effects through both processes so-called blocking
and supressing mechanisms. Carcinogenesis can be blocked by prevention of ROS attack on
DNA, as well as by decrease of prolonged inflammation. Mechanisms that result in cancer or
tumor suppression include growth inhibition by induction of cell cycle arrest and/or apoptosis
(19, 41). Accumulating evidence demonstrated a better control of cancer mortality by
preventing cancer cells from progressing to advanced stages rather than curing when reaching
malignancies, where available therapeutic options are very limited.
Consumption of fruits and vegetables has been associated with cancer risk reduction
due to their containing of dietary bioactive compounds. One major advantage of these natural
bioactives is that they generally have fewer adverse effects in comparison to pharmaceutical
drugs after long-term administration. In addition, combination of these phytochemicals have
demonstrated higher efficacies than isolated compounds, indicating possibilities to improve
anticancer strategies (2, 41). Since our understanding of molecular mechanisms underlying such
synergistic effects between compounds is limited, in this dissertation, we demonstrated the
chemopreventive effects, anti-inflammatory properties, as well as the cytoprotective effect of
allyl isothiocyanate (AIT) and sulforaphane (SFN) in combination. In addition to the AIT-SFN
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combined treatment, other phytochemicals including luteolin (LUT), and curcumin (CUR) were
also used to combine with the aforementioned bioactives and were tested on their enhanced
anti-inflammatory properties. These bioactive compounds were chosen based on their biological
properties and their sources which are natural diet-based. AIT and SFN are ITCs found in
cruciferous vegetables. AIT, also known as mustard oil, can be obtained from mustard seeds
whereas SFN can be obtained from broccoli. While CUR is rich in turmeric, LUT can be found in
wide range of diets such as oregano, celery, carrot, and pepper. In this study, combination
treatments of each two bioactives represented the effects from two different foods
consumption.
As shown in Figure 6.1, the combination between AIT and SFN could prevent cancer
initiation by enhancing each other’s effects as antioxidants. In this case, combined pretreatment of AIT (0.25 - 1.25 µM) and SFN (0.01 - 0.05 µM) at a ratio of 25:1 synergistically
protected RAW 264.7 macrophages against a free-radical generator tert-butyl hydroperoxide (tBHP)-induced damage by increasing cell viability, and decreasing cellular ROS. The antioxidant
effects of these isothiocyanates (ITCs) including their combination were clearly completed
through phase 2 antioxidant and detoxification proteins including GSH, GST, HO-1, and NQO-1,
some of which had more dominant effects than the others, under partial regulation of Nrf2, and
NF-B transcription factors.
In addition, the combination between AIT-SFN, as well as SFN-LUT, AIT-LUT, and AITCUR possessed anti-inflammatory properties, which could block tumor cells from being initiated
as well. In this case, the following ranges of concentrations were used: AIT (2 - 10 µM), SFN (0.25
- 1.25 µM), LUT (5 - 25 µM) and CUR (2-10 µM). AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1),
and AIT-CUR (1:1). At these indicated ratios, synergistic decrease of lipopolysaccharide (LPS)induced nitic oxide (NO), and pro-inflammatory cytokine IL-6 in RAW 264.7 cells were observed.
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We also showed that their anti-inflammatory effects partially involved NF-B pathway, which
regulated expression of other proteins such as iNOS, COX-2, IL-6, IL-1β, and IL-10. In addition,
the combined treatment also increased the expression of HO-1, which is an antioxidant protein,
to counteract ROS generated during inflammation.

Figure 6.1 Stages in carcinogenesis inhibited by AIT, SFN, and their combination. Adapted from
reference (18) and experimental results discovered in chapter 3 - 5.
(*) Phase 2 antioxidant and detoxification proteins induced by ITCs under oxidative stress
include Nrf2, HO-1, NQO-1, GSH, and GST.
(**) ITCs decreased iNOS, COX-2, IL-6, IL-1β, and IL-10, partially through the regulation of NF-B.
(#) Decreased cyclin B1 expression, and increased p21 expression by ITCs led to cell cycle arrest
at G2/M phase.
(##) Expression of pro-apoptotic proteins such as p53, cleaved caspase-3, and cleaved PARP
were decreased by ITCs while expression of an anti-apoptotic protein, survivin, was decreased.
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In case of cancer suppressing mechanisms, AIT-SFN (1.25:1) combined treatment under
dose ranges of 2.5 – 12.5 M, and 2 – 10 M, respectively provided synergistic multi-target in
the system of proliferation and migration of A549 non-small cell lung cancer cells. The treatment
inhibited cancer cell growth by inducing apoptosis and cell cycle arrest. We demonstrated an
induction of apoptosis with an increase expression of pro-apoptotic proteins such as p53,
cleaved caspase-3, and cleaved PARP as well as a decrease expression of an anti-apoptotic
protein, survivin. We also showed G2/M phase cell cycle arrest by decreasing protein expression
of cyclin B1 and increasing protein expression of p21. For cell migration, essential proteins such
as COX-2, and p-STAT3, as well as MMP-9 were decreased.
Although the concentration ranges and the combination ratios between AIT and SFN
used in each approach were different, the combined treatment between these two compounds
could provide synergistic effects as antioxidants, anti-inflammatory, and chemopreventive
agents. In addition, the concentration ranges of AIT, SFN, LUT, and CUR used in this study were
reasonable in comparison to the concentration of each compound found in serum of rats and
mice after an oral administration (ITCs, and LUT), or intravenous administration (CUR) (8, 44, 95,
126). This information suggests a high possibility to obtain similar synergy in an in vivo model.
Since the aims of study were completed using three different cell culture models, further study
using co-culture systems or animal models are necessary to demonstrate how the combination
treatments perform as in a complex system. It is also good to note that dietary phytochemicals
including the compounds used in this study can be metabolized in cells and tissues. Therefore,
further studies of their metabolites will allow us to find their active forms and better approach
their enhanced effects on cancer prevention and therapy.
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